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Abstract 
Spinal cord injury (SCI) remains one of the most devastating conditions in medicine; it is a 
complex medical condition with no cure currently available. Inflammation plays an important 
role in SCI as it can have both beneficial and detrimental effects. Cell therapy has emerged as 
a promising treatment for SCI due to the potential for stem cells, including multipotent 
mesenchymal stromal cells (MSC), for tissue regeneration and immunomodulation of the 
inflammatory cascade after the initial trauma. However, there are still important, unresolved 
questions regarding cell therapy that magnetic resonance imaging (MRI) can help to address 
by producing high-resolution images with exquisite soft tissue contrast in a non-invasive, 
non-destructive and three-dimensional (3D) manner, allowing a dynamic view of changing 
pathology and cellular events in vivo.  
In this thesis in vivo longitudinal imaging of SCI in mouse and rat models is presented using 
MRI. A resolution of 200µm in all three planes was achieved using a balanced steady state 
free precession (bSSFP) pulse sequence in a 3T whole-body clinical scanner. Using iron 
oxide particles as a contrast agent, cellular MRI was used to assess direct MSC 
transplantation in a mouse model and acute inflammation in a rat model. This was the first 
study to use cellular MRI for cell tracking in a mouse SCI model. We report on the use of 
cellular MRI to locate transplanted cells and monitor their overall distribution as well as to 
evaluate the delivery of transplanted cells to the target tissue in the early phase. Limitations 
of long-term cell tracking using iron oxide are also discussed. This is also the first study 
using cellular MRI to image in vivo cells associated with the inflammatory response within 
the lesion in a rat SCI model and the first demonstration of the use of bSSFP at 3T for rat 
body imaging.  
Having the tools for longitudinal in vivo cell monitoring in SCI will help gain a better 
understanding of both inflammation and response to cell therapy. As these tools are refined, 
they can be used to test different potential treatments for SCI and optimize them. 
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Chapter 1  
1 General Introduction 
Spinal cord injury (SCI) is one of the most devastating conditions in medicine; besides 
the lives lost, for those who survive, there is a loss of productive life years and a high 
economic burden placed on our society. It is difficult to determine the world wide 
incidence and prevalence of SCI1, 2 but it is estimated that there are 4,259 new cases in 
Canada each year; 42% of these cases are traumatic injuries and 58% result from non-
traumatic causes.3 In Canada the primary cause for SCI is car collisions, which account 
for 35% of cases. Falls are the second largest cause, producing 16.5% of the new 
injuries.4 This chapter will include a general overview of the spinal cord, injury 
mechanisms, magnetic resonance imaging (MRI), and cellular MRI. 
 
1.1 The Spinal Cord  
The central nervous system (CNS) includes the brain and the spinal cord. The spinal cord 
has been described as the “highway” connecting the brain to the rest of the body. This 
highway carries information through the ascending (sensory) tracts to the brain and 
through descending (motor) tracts to the rest of the body. The human spinal cord can be 
divided in segments according to the spinal nerve pairs that enter and leave the spinal 
cord: 8 cervical, 12 thoracic, 5 lumbar 5 sacral, and 1 coccygeal.5  The spinal cord is 
surrounded and protected by connective tissue, called the spinal meninges: the pia mater, 
adhered to the surface of the spinal cord; the arachnoid mater, which encloses the 
subarachnoid space, where the cerebrospinal fluid (CSF) is contained; and the dura mater, 
attached to the spinal canal within the vertebral column. Besides neurons, other 
supporting cells are present in the spinal cord: oligodendrocytes, which form a myelin 
sheath around axons; astrocytes, which surround blood vessels, helping to form the blood 
brain barrier (BBB) and holding structures together; microglia, which are the resident 
macrophages of the CNS; and, ependymal cells, another element of the BBB, lining the 
spinal canal.6 
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Figure 1.1: The spinal cord connects the brain to the rest of the body, serving as a 
highway of information that transmits and integrates incoming and outgoing information. 
Modified from the NIH Office of Science Education.7  
 
1.2 Spinal Cord Injury 
When the spinal cord is injured, the communication pathways between the brain and the 
rest of the body are interrupted. Besides the more evident consequence of decreased 
muscle control and paralysis, other effects from SCI may include: loss of sensation, 
diminished thermal and blood pressure regulation, decreased breathing capacity, loss of 
bladder and bowel control, spasticity, autonomic dysreflexia, sexual dysfunction, and 
pain.8  
1.2.1 Primary Traumatic Spinal Cord Injury 
The primary traumatic injury is usually the result of an initial impact to the cord due to a 
fracture, dislocation, foreign object impact, or a ruptured disc, combined with a persisting 
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compression.  In some cases this results in a laceration or even complete transection.9 The 
mechanical injury causes immediate cell death at the site of impact and disrupts the blood 
spinal cord barrier. 
 
Figure 1.2: The initial injury to the spinal cord produces blood spinal cord barrier 
disruption and cell death at the point of injury. This figure illustrates a cervical SCI, 
where a bone fragment has impacted the cord. 
1.2.2 Secondary Injury 
Impaired sensory and motor function in people who have a SCI comes not only from the 
initial traumatic event, but also from a ‘secondary’ injury, which further damages the 
neural pathways, exacerbating motor and sensory deficits. These secondary processes 
include hypoxia, excitotoxicity, and lipid peroxidation, and will trigger an inflammatory 
response causing additional cell death.10 The consequences of this ‘secondary’ injury 
commonly include: hemorrhage, edema, necrosis, demyelination and cyst formation.11  
1.2.3 Inflammation In SCI 
The inflammatory response after SCI is triggered by cells within the damaged tissue (e.g. 
endothelial cells) that will release pro-inflammatory cytokines and chemoattractants.12 
This results in an influx of leukocytes, with different timelines for specific cells. In 
humans, neutrophils will enter the cord within 4 hours after SCI, with maximum 
distribution in the gray matter (GM) and white matter (WM) at 1-3 days, and will cease 
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to enter by 10 days.  Peripheral macrophages will be most abundant in the cord at 5-10 
days after SCI, and then their influx slowly decreases with time, although they may still 
be present for weeks to months. Microglia become activated 1-3 days after injury, 
becoming ‘foamy’ macrophages by 5-10 days, and persisting for weeks and up to a 
year.13   
Inflammation due to SCI in rats has a similar timeline.  This has been described by Sroga 
et. al who showed that neutrophils appear at the lesion site within a few hours of the 
initial injury, reach a peak 12-24 hours after the injury and then disappear by 5 days.  
They also showed that, like in human SCI, macrophages infiltrate the cord 2 days after 
the injury, reaching a peak 5-7 days after SCI and microglia become activated within 
minutes to hours after the SCI, both persisting for weeks to months.14  
In mouse SCI there is a similar time course for infiltration and activation of macrophages 
and microglia; however, the neutrophil response is different. The initial neutrophil 
infiltration still starts within hours after SCI, and the peak is reached 3-7 days after 
injury, depending on strain. However, in mice neutrophils increase again 2 weeks after 
injury and are still present at the SCI up to 6 weeks after injury.15  
Macrophages were considered to have a dual, ‘double-edged’ role in SCI.16, 17 Recent 
literature has shown that this may be in fact due to two separate subsets of macrophages 
present at the lesion site.18, 19 Classically activated macrophages (M1) are thought to have 
a negative role in SCI by exacerbating the injury through the release of toxic by-products 
and by amplifying the inflammatory responses. Alternatively activated macrophages 
(M2), have been shown to have a positive role in SCI by contributing to the debridement 
and healing process.18 Furthermore, Kigerl et al. have shown that during the first 1-3 days 
after SCI the presence of M1 and M2 is equivalent, but by the end of the first week the 
M2 have mostly disappeared and the M1 dominate.18 
1.2.4 Animal Models 
In order to better understand the mechanisms of SCI and to explore potential treatments, 
animal models of SCI have been developed. Different methods have been used to mimic 
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the initial mechanical injury that occurs during SCI in humans, such as contusion,20 
compression,21, 22 and transection.23 In this thesis a clip compression model is used which 
involves the use of a modified aneurysm clip. The clip uses a C-shaped spring that can be 
calibrated to close at a chosen force such as: 3g, 8g, 24g for mouse or 20g, 35g, 50g for 
rat, that will result in different severities of SCI (mild, moderate, severe, respectively).22, 
24 A laminectomy is performed to expose the cord at the level where the injury will be 
induced; 4th thoracic (T4) in this thesis. The clip is placed around the cord extradurally 
with one blade of the clip placed on the ventral side of the cord and the other blade on the 
dorsal portion; the calibrated spring is then released and left closed for 1 minute. Then the 
clip is removed, muscle and skin layers closed, and the animal is allowed to recover from 
surgery. The clip compression mimics mechanisms that occur in human SCI as it has two 
components, an initial quick contusion and a sustained compression that results in 
ischemia.  The clip compression SCI model can be performed with low variability.  Joshi 
and Fehlings22 and Fehlings and Tator25 showed a strong correlation between  the scoring 
for behavioral testing, histological outcomes, and the severity of SCI in mouse and rat 
models, respectively.  
Rodents are most commonly used as the animal model for SCI.  Rats have been used 
most widely26 due in part to size and model development (the first model described was 
in dogs and initially adapted to rats), preference and availability27 and, most importantly,  
pathology similarities to SCI in humans.13, 14 Differences in the inflammatory responses 
to SCI for rats and mice are described in the previous subsection (1.2.3).  These 
differences contribute to differences in the appearance of the lesion. The lesion in rats is 
characterized by extensive degeneration of GM and WM, apparent at 1 week post-injury, 
which increases as rats develop cysts filled with substantial debris.28 In mice the relative 
lesion (with respect to cord size) is initially larger but mice show wound contraction as 
connective tissue develops at the lesion site similar to the process observed in skin 
wounds; another feature in the mice is that they do present small cavities initially, but 
these disappear over time.28 
Mice have become an increasingly popular model due to the availability of transgenic 
strains. Transgenic mice are genetically modified such that either a gene is removed to 
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study function loss related to that gene or an exogenous gene is added to study function 
gain and better understand the role of each gene in different functions.29 Use of 
transgenic mice in SCI research has allowed for a better understanding of the 
pathological consequences of SCI; for example, to study the role proteins such as EphA4 
(ephrin type-A receptor 4) and GFAP (glial fibrillary acidic protein) will play in the 
formation of glial scar or the role of LIF (leukemia inhibitory factor) protein in enhancing 
the microglial/macrophage response.30, 31 Transgenic mice can also be used to study 
factors that affect axonal regeneration such as Nogo (Neurite outgrowth inhibitory 
molecule), MAG (myelin associated glycoprotein), OMgp (oligodendrocyte myelin 
glycoprotein) or interactions among them. 29 
Rodent models are also widely used to study regenerative treatments for SCI.32, 33 
Luchetti et al. compared SCI in immune-competent C57BL/6 and BUB/BnJ mice and 
non-obese diabetic severe combined immunodeficient (NOD-SCID) mice to investigate 
potential differences in the inflammatory responses that might impact stem cell 
transplantation for SCI. The authors reported that there were no differences in the 
inflammatory response that would affect neurotransplantation studies; while there were 
some variations in neutrophil infiltration, macrophage/microglia numbers present at the 
lesion were not different among strains and there was no significant difference in lesion 
volume between strains either.34  
 
1.3 Stem Cells 
Stem cells are fundamental in the formation of all multi-cellular organisms.35 They have 
the unique characteristics of unlimited self-renewal and the ability to differentiate. 
Totipotent stem cells can differentiate into any type of cell, pluripotent cells can 
differentiate into any type of cell in the body except those needed to support and develop 
a fetus in the womb (amnion, chorion, and other components of the placenta), multipotent 
cells can differentiate into a variety of cell types (though usually only into cell types from 
the same tissue where they are located) and unipotent cells have dedicated differentiation 
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to one linage.35 When a stem cell divides, each new cell has the potential either to remain 
a stem cell or become another type of cell with a more specialized function.  
The term “stem cell” has been around for over a century now36 but it was in the late 50’s 
and 60’s when research and many clinical trials started using adult stem cells for cancer 
treatment,37, 38 which is thought of as the first therapeutic use of stem cells. It has only 
been in the last 30 years that the term “embryonic stem cell” was coined39 and that 
research in the stem cell field has really boomed. Some of the most important questions 
currently being pursued in stem cell research are: “What are the core genetic and 
epigenetic regulators of stem cells? What are the extrinsic, environmental factors that 
influence stem cell renewal and differentiation? And how can the answers to the first two 
questions be harnessed for clinical benefit?”40 While a lot of effort has been geared 
towards defining what is a “true stem cell”41 one thing agreed on is the classification 
according to their origin, into embryonic and adult stem cells.  
1.3.1 Embryonic Stem Cells (ESC) 
First named in 1981 by Martin,39 these cells are derived from the inner cell mass of the 
blastocyst and are pluripotent, they can produce cells of all 3 germ layers (mesoderm, 
endoderm and ectoderm) that can differentiate in all types of adult tissues. 
 
Figure 1.3: Embryonic Stem Cells are derived from the inner cell mass in blastocyst 
and are pluripotent, they have the potential to differentiate into all cells present in adult 
tissues. 
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ESC gained a lot of attention as a promising therapy for incurable diseases due to their 
potential to differentiate into any type of adult tissue and the fact that they can be grown 
in vitro almost indefinitely without loosing their self-renewal or differentiation 
potential.42 However, ESC also pose potential risks. Most worrisome is the possibility for 
teratoma formation due precisely to their capability to maintain their differentiation 
potential for long periods of time and be able to differentiate into cells from all 3 germ 
layers, so they are unlikely to be used for therapy in their undifferentiated state.42 This 
has been reported in both experimental and clinical ESC transplantation research.43, 44 
In SCI, embryonic stem cells have been studied in models for several years45-47 but due to 
regulatory caution clinical studies are just beginning, in the US through Geron 
Corporation.48, 49 
1.3.2 Adult Stem Cells 
Adult stem cells can be derived from various tissues, including bone marrow (BM), 
peripheral blood, brain, spinal cord, dental pulp, blood vessels, skeletal muscle, epithelia 
of the skin and digestive system, cornea, retina, liver, and pancreas.35 Adult stem cells are 
found in the postnatal organism, where they function as the internal repair system. Their 
capacity for self-renewal varies by tissue. For example, in the gut and BM stem cells 
regularly divide to repair and replace worn out or damaged tissues, while in the pancreas 
and heart, stem cells only divide under special conditions. Adult stem cells are capable of 
differentiation, though usually only into cell types from the same tissue where they are 
located, thus being labeled multipotent or unipotent.40 On the other hand, they have also 
shown plasticity50 and pluripotency51.  
Within the adult stem cells, BM-derived stem cells have gotten a lot of attention for their 
potential for autologus transplant, where the cells are obtained from the patients own BM 
and expanded in vitro, and so avoid rejection. Another feature that makes them an 
attractive option for transplantation is that, unlike ESC, they are not associated with 
tumor formation and do not present the same ethic concerns ESC do. BM-derived stem 
cells can be divided into Hematopoietic Stem Cells (HSC) and Multipotent Mesenchymal 
Stromal Cells (MSC). 
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1.3.2.1 Hematopoietic Stem Cells (HSC) 
HSC can be found in the blood and BM and will form blood components: erythrocytes, 
platelets, and immune cells (lymphocytes, monocytes, neutrophils, eosinophils and 
basophils).35 
  
Figure 1.4: Hematopoietic Stem Cells can differentiate in blood and immune cells and 
can be found in the BM and blood. From Wikipedia’s “Blood cells differentiation chart” 
Author: ????? Used under the Creative Commons Attribution-Share Alike 3.0 
Unported license.  
HSC are the stem cells that have been used in therapy the longest, and are still currently 
routinely used for treatment of leukemia52, 53 and other disorders such as immune 
deficiencies.54 In the context of SCI, they have been used in animal models,55, 56 where 
functional recovery was reported as assessed by locomotor testing. They have also been 
used for SCI patients in clinical trials which used direct transplantation of HSC into the 
cord,57 where improvement in both motor function and sensation was reported, and HSC 
delivered by lumbar puncture was feasible, safe, and well tolerated by the patients 
involved in the study.58  
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1.3.2.2 Multipotent Mesenchymal Stromal Cells (MSC):  
As mentioned in this section’s introduction, a lot of effort has been geared towards 
defining a “true stem cell” and MSC have been no exception. This acronym has been 
used for both mesenchymal stem cells and for multipotent mesenchymal stromal cells. 
This nomenclature is accepted as long as it is clearly defined in each publication.59  In the 
work presented here, MSC stands for multipotent mesenchymal stromal cells, which are 
defined as plastic-adherent cells derived from BM, adipose and other tissues that have 
shown multipotency in vitro; while the phrase mesenchymal stem cells is to be reserved 
for plastic-adherent cells that can self-renew long term and show multipotency in vivo.59 
  
Figure 1.5: BM-derived multipotent mesenchymal stromal cells can differentiate into 
cells from different types of tissues. ©2001 Terese Winslow (assisted by Lydia Kibiuk 
and Caitlin Duckwall). Used here with kind permission from T. Winslow. 
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MSC can be derived from many different tissues, including BM, adipose tissue, and 
muscle, and have the potential to differentiate into bone, fat, cartilage and muscle.60 
There is substantial ongoing research in the field, but specifically applicable to SCI is the 
fact that MSC have also shown to differentiate into neural cells.61, 62  
In the last decade MSC have been explored as an option to promote functional recovery 
following SCI. For example, in a rat model Cızkova et al. reported remyelination of 
spared white matter tracts and enhanced axonal growth that was reflected in motor 
improvement, which was assessed using the Basso–Beattie–Bresnahan behavioral test.63 
Lee et al. also reported some motor and sensory recovery using the Basso–Beattie–
Bresnahan scale, improved conductivity in the sensory components of the cord measured 
through somatosensory evoked potentials (SSEP), and neural differentiation.64  In a non-
human primate model, neurogenesis has been reported as well as functional improvement 
as measured by SSEP.65  
In the last 5 years a few clinical studies using autologous MSC transplant for spinal cord 
injury have been done. In one of the first studies Sykova et al. (Czech Republic) used un-
manipulated BM, which contained both MSC and HSC, for transplant into 20 patients 
divided in 2 groups: chronic and subacute SCI, either by intravenous (i.v.) or intra-arterial 
(i.a.) infusion. In this study improved motor and sensory function after three months was 
observed mostly in subacute patients that had received the i.a. infusion.66 In another study 
by Moviglia et al. (Argentina) MSC were co-cultured with the patients’ own T-cells and 
injected in 2 chronic SCI patients by i.a. infusion. Both patients showed motor and 
sensory improvement.67 Other reports have followed; Chernykh et al. (Russia) also used 
whole BM, containing both MSC and HSC, and performed both direct and i.v. delivery of 
the cells in patients with chronic SCI and reported the procedure was feasible, safe and 
improved neurological status in the patients that received the treatment versus controls.68 
A study in India where BM-derived MSC were transplanted by lumbar puncture in 30 
SCI patients reported safety and some sensory recovery.69 Contrary to the previous 
positive reports, a more recent study by Kishk et al. (Egypt) where an intrathecal 
transplant of MSC was performed in 44 SCI patients reported no significant neurological 
improvement but suggests caution as negative effects included spasticity and neuropathic 
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pain and one patient with a history of post-infectious myelitis presented post-transplant 
encephalomyelitis.70 A new study from Korea explored the use of adipose tissue-derived 
MSC and reported no adverse effects after autologous i.v. transplantation in 8 chronic 
SCI patients.71 With most of these initial findings reporting safety and feasibility, more 
studies are likely to come, particularly since one has raised concerns for adverse effects. 
These studies have been in small groups of patients so larger trials are needed. One of the 
issues is that makes it difficult to establish the pure effects from MSC transplantation in 
these studies is that the transplant protocols have used a combination of cell population, 
or concurrent pharmaceutical and/or rehabilitation regimes. 
1.3.3 Cell Therapies 
It is now being understood that cell therapies are likely to exert their effects by two 
mechansisms; replacement of the tissue and trophic support.72 Phenotypic replacement 
involves the integration of transplanted cells to damaged tissue according to specific 
diseases.  For example, transplanted cells could differentiate into neurons for SCI, 
Parkinson’s disease, or traumatic brain injury; into oligodendrocytes for remyelination; or 
into motor neurons or astrocytes that would provide neuroprotection. On the other hand 
transplanted cells could provide trophic support by releasing growth factors and 
cytokines that will modulate the immune response and by inhibiting glutamate toxicity 
and promoting angiogenesis.72  
The goals of using cellular therapy for SCI include “to bridge any cysts or cavities, to 
replace dead cells, and to generate a favorable environment for axon regeneration”.73 
Different cell types have been used in preclinical models for SCI besides MSC and HSC; 
as described in the previous sections, these have also included Schwann cells (SC), 
olfactory ensheathing cells (OEC), neural stem/progenitor cells (NSPC) and fate-
restricted neural and glial precursors.74 While the exact mechanisms are not completely 
understood, some of the trophic effects reported following transplantation after SCI 
include: a decrease in macrophages and pro-inflammatory cytokines in some cases, and 
in others a change in macrophage phenotype and function, in the form of an increase in 
M2 macrophages that could promote neuroprotection and axon regeneration.19 
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Recent and on-going Phase I and Phase II clinical trials for SCI include transplantation of 
MSC,75 HSC,76 OEC,77 and macrophages,78 to determine feasibility and safety.19 There 
are still many important, unresolved questions about the best strategies for stem cell 
therapy.  For example: what is the optimal cell dose? what is the best route for delivery of 
stem cells? where do the cells go after their administration? how long do cells remain at 
the transplant site? do cells migrate away from the transplant or target sites within the 
CNS or to other tissues in the body? And what is their long-term safety? In order to better 
understand the fate of administered stem cells and to develop and optimize stem cell 
therapy protocols, methods are needed to allow for in vivo monitoring of the cells over 
time.79, 80 The focus of this thesis is on the use of MRI as a method for in vivo cell 
tracking. 
 
1.4 Magnetic Resonance Imaging (MRI) 
MRI is a powerful technique that provides excellent soft tissue contrast and high-
resolution images. As the human body has a high water (H20) content, traditional MRI 
focuses on protons, since a 1H nucleus has a single proton. Even though there are other 
elements that can be imaged with MRI, this thesis focuses on proton imaging. The most 
important natural properties of 1H for MRI, which will be used in the next sub-sections, 
are proton density (PD), which is the number of 1H atoms per unit volume, and two 
characteristic times: T1, which is called the spin-lattice relaxation time and T2, the spin-
spin relaxation time.81 
1.4.1 Nuclear Magnetic Resonance (NMR) 
Atomic nuclei have four physical properties: mass, electric charge, magnetism and ‘spin’, 
an intrinsic angular momentum, which comes in ½ multiples that can be + or - with 1H 
having a spin of ½.82 Once these nuclei are placed in the presence of an external magnetic 
field (B0), these momentums or spins will tend to align with it, creating a net magnetic 
moment. The gyromagnetic ratio is a constant for each nucleus that represents the ratio of 
its magnetic dipole moment to its angular momentum.81 1H has a gyromagnetic ratio of:  
14 
 
𝛾2𝜋 = 42.57𝑀𝐻𝑧𝑇  
As they can’t completely align with B0, the protons will experiment a torque that makes 
them precess about B0 at the Larmor frequency: 𝜔! = 𝛾𝐵! 
In the presence of B0 a net magnetization moment is produced, as not all protons will 
align in the same direction (parallel) as B0, some will align in opposite direction 
(antiparallel). Because the parallel direction requires less energy, there will be a greater 
fraction of the protons which are aligned in the parallel direction with B0 generating an 
equilibrium nuclear magnetization (M0) proportional to B0.83 For 1H M0 will be: 
𝑀! =  𝜌𝛾!ℏ!𝐵!4𝑘𝑇  
where ρ is the density of protons, ħ is Planck‘s constant divided by 2π, k is Boltzmann’s 
constant and T is absolute temperature.  
Using these NMR principles a sample dependent signal can be generated. This process 
can be broadly described in four steps: 
1) Place sample in the magnet, where there is a constant magnetic field producing a 
an equilibrium magnetization along B0 described by 
𝑀! = 𝑀!(1− 𝑒!! !!) 
T1 is the spin-lattice relaxation time, a time constant to develop longitudinal 
magnetization (Mz). T1 is tissue specific and B0 dependent. When the sample is 
initially placed in the magnet, before any excitation, Mz=M0 after ~5T1. 
2) Excite the system by applying a time-varying magnetic field (B1) perpendicular to 
B0 using a short radiofrequency (RF) excitation pulse, in order to ‘tip’ the spins 
around that new magnetic field.  
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3) Wait and receive. Once B1 is turned off, the spins will be precessing around a 
transverse plane Mxy generating an electromagnetic field in a receiving RF coil. 
As the protons return to equilibrium, the magnetization that had been induced on 
the transverse plane (Mxy) by B1 starts decreasing, decaying at a rate of: 
𝑀!" = 𝑀!𝑒!! !! 
Where T2 is the transverse or spin-spin relaxation time, a time constant that 
describes the decay of the transverse magnetization (Mxy), and is tissue specific.  
4) Analyze data. As a receiving RF coil experiences an electromagnetic field, a 
signal from the sample is measured and a Fourier transform is then applied to find 
the frequency components of the measured signal.   
1.4.2 MRI Basics 
MRI uses those NMR principles to generate a signal that can be measured to produce an 
image. As mentioned above, T1 and T2 are time constants specific to each tissue so, in 
MRI, each tissue will have different signal intensity in an image due to T1 and T2 
differences and due to their PD. In order to generate an image from those measured 
signals, the location of each point in the sample or tissue generating a signal needs to be 
spatially encoded. Gradient coils are used to linearly vary the static magnetic field so that 
the nuclei will precess at slightly different frequencies, which can then be used to 
distinguish different positions in space.81  
1.4.3 Pulse Sequences 
There are different pulse sequences used to produce MRI images. As mentioned in the 
previous section, Mxy is measured. However, if only one RF excitation pulse was applied 
and we waited indefinitely, Mxy would only decay to zero and that would be the end of 
the signal. In MRI pulse sequences are used to control Mxy by applying different RF and 
gradient pulses so that, instead of always decaying, Mxy can be dephased and rephased 
according to the pulse sequences. The rephasing period effectively creates a signal echo, 
where the signal is measured.81 The echo time (TE) describes the time from the RF 
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excitation to the maximum echo, when the signal is read. The repetition time (TR) 
describes the time between each excitation. In general, pulse sequences can be divided in 
spin echo (SE) and gradient echo (GE).  
1.4.3.1 Spin-Echo (SE) 
In the case of the SE sequence, a 90° RF pulse is applied and the spins are allowed to 
dephase around the transverse plane (xy) for a certain time before a 180° RF pulse is 
applied that will rephase the spins. Different contrast can be acquired with SE sequences 
that will depend in TE and TR:81 
 
TE 
Short (<40ms) Long (>75ms) 
TR 
Short (<750ms) T1-weighted ------ 
Long (>1500ms) PD-weighted T2-weighted 
While SE is a basic pulse sequence, other sequences based on it have been developed for 
faster imaging with dominant contrast, these include:  
• T1-weighted: inversion recovery (IR), fluid attenuated inversion recovery 
(FLAIR), and short TI inversion recovery (STIR) 
• T2-weighted: turbo/fast SE (FSE), turbo gradient and SE (GRASE), Single-shot 
FSE (SSFSE) or Half Fourier single-shot turbo SE (HASTE), and SE-echo planar 
imaging (SE-EPI).81 
1.4.3.2 Gradient-Echo (GE) 
A GE sequence will also start with an RF pulse, but this flip angle (α) will be less than 
90°, which will allow for faster imaging since less time is required for protons to return to 
equilibrium. In this case, instead of using a second 180° RF pulse to generate the echo, a 
negative gradient will help the protons rephase, but because this will only account for the 
gradient effects, it will not account for the dephasing due to local inhomogeneities in the 
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magnetic field, making GE sequences sensitive to T2* (a spin-spin relaxation time that 
includes contributions from molecular interactions as well as inhomogeneities in the 
magnetic field) effects. Again contrast will depend on imaging parameters:81 
 
TE 
Short (<15ms) Long (>30ms) 
α 
Small (<40°ms) PD-weighted T2*-weighted 
Large (>50°ms) T1-weighted ------ 
GE sequences are ideal for 3D due to their short TR, though they also are advantageous 
in 2D for dynamic enhancement and breath-hold studies. While GE is the other basic 
pulse sequence, additional sequences have been developed. GE sequences can be 
categorized according to their dominant contrast, these include:  
• T1-weighted: spoiled GE, magnetization prepared rapid acquisition by gradient 
echo (MP-RAGE), turbo fast low angle shot (Turbo-FLASH), and multi-shot EPI, 
GE-EPI 
• T2/T1-weighted: fully balanced GE and balanced steady state free precession 
(bSSFP) 
• T2- or T2*-weighted: SSFP and double echo steady state (DESS)81 
While they are loosely classified in this way, there can be some overlap.   
1.4.3.3 Balanced Steady State Free Precession (bSSFP)  
In this thesis we use the bSSFP imaging sequence. While this pulse sequence was 
described over half a century ago84 it only has become practical to use in the last decade 
or so. bSSFP had been limited by banding artifacts, which appear as bands of low signal 
across the images. These bands are worst at areas with substantial magnetic field 
inhomogeneity such as at air-tissue interfaces. In order to minimize this banding, a very 
short TR and the best possible shimming are required.85 Technological advances have 
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improved MRI hardware, including faster gradient amplifiers and more homogeneous B0, 
which have resulted in more robust scanners that allow shorter TR times and have 
substantially decreased inhomogeneities.86, 87 As advances are made in MRI, different 
vendors will use their own names and acronyms for products based on the same concepts; 
bSSFP is also known as True-FISP (Siemens) and FIESTA (Fast imaging employing 
steady state acquisition, GE) but should not be confused with the other rapid SSFP GE 
sequences that are not balanced. The difference between bSSFP and the other fast GE 
sequences is a different gradient pattern.  
 
Figure 1.6: bSSFP pulse sequence diagram. RF: radiofrequency pulse, GSS: Slice select 
gradient, GPE: Phase encode gradient, GFE: Frequency encode gradient.88  
In bSSFP a preparation negative gradient is applied within each TR so that the gradient 
dephasing between each excitation is zero. Since the negative gradient will only refocus 
the proton dephasing due to the positive gradient and will not compensate for 
inhomogeneities in B0 or spin-spin interactions, bSSFP will be sensitive to T2* effects. 
bSSFP has a complex contrast, it is T2/T1-weighted for an optimal α, which can be 
calculated from:88 
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cos ∝ ≃ !!!! − 1!!!! + 1 
One of the characteristics of bSSFP is that it has “the highest possible signal-to-noise 
(SNR) ratio per unit time”.86 Assuming TR<<T1,T2 the on-resonance signal intensity can 
be expressed as:88 
𝑀!! ≃ 𝑀! 𝑠𝑖𝑛 ∝1+ 𝑐𝑜𝑠 ∝ +(1− 𝑐𝑜𝑠 ∝)(!!!!) 
Using an optimal α then the on-resonance signal intensity can be expressed as:88 
𝑀!! ≃ 12𝑀! 𝑇!𝑇! 
So for tissues where T2≈T1, and with a high α (70°-90°) Mss approaches half of M0.86 
bSSFP has been used for clinical applications showing that the speed and T2/T1 contrast 
is valuable for cardiac and vascular imaging, where the T2/T1 ratio of blood and 
surrounding tissues is significantly different.89, 90 In the field of cellular MRI, the 
sensitivity of bSSFP to inhomogeneities has made it effective for tracking iron labeled 
cells .91-97 
1.4.4 Contrast Agents 
Contrast agents are chemicals injected into the body in order to alter the relaxation times 
of tissues by decreasing T1 or T2, so that as the contrast agent reaches the target (e.g. 
tissue or vasculature) the signal is enhanced as either a hyper- or hypo-intensity with the 
background tissues remaining the same so that their signal intensity is not altered.81  
Contrast agents are typically used to aid in the detection of pathologies by enhancing 
their contrast compared to the surrounding tissue. 
When placed within a large magnetic field any material, including tissues can become 
temporarily magnetized. The degree at which they will do so is called magnetic 
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susceptibility (χ), which is a natural property and is different for different materials and 
tissues: water is slightly diamagnetic (χ<0), air and dense bone have almost zero 
susceptibility, though only vacuum is nonmagnetic (χ=0). The ensuing inhomogeneity 
will be worse at the edge of two materials with different susceptibilities and in some 
circumstances fairly severe local inhomogeneities may result.83 Materials can be 
classified in four groups from less to more susceptibility:  
• Diamagnetic  materials, with weak susceptibilities that may in fact cause an 
internal field opposite to B0 (χ<0); most body tissues fall within this range. 
• Paramagnetic  materials, which have a stronger susceptibility causing an 
internal field in the same direction as B0 (χ>0); examples include gadolinium, 
deoxy-hemoglobin and met-hemoglobin. 
• Superparamagnetic  materials include iron oxide particles, ferritin and 
hemosiderin. 
• Ferromagnetic  materials are strongly magnetized that experience a large force 
in the presence of B0; examples include metal alloys containing iron, nickel and 
cobalt.81  
1.4.4.1 T1 Shortening Agents  
T1 shortening agents are generally based on gadolinium (Gd). Because by itself the Gd 
ion is toxic, it is chelated to a ligand such as diethylene-triamine penta-acetic acid 
(DTPA, as in Magnevist® by Schering) to isolate it from the body. Gd-based contrast 
agents are delivered i.v., usually by bolus injection and will shorten T1 and T2, in the 
tissues where it accumulates. However, at the low doses used clinically, the effect on T1 
is much larger. In the clinic typically T1-weighted images are acquired before and after 
the administration of a Gd agent and in the post-Gd images the signal in areas where Gd 
accumulates becomes hyper-intense. Gd-based agents are generally excreted renally and 
will be cleared in about 24hrs. Gd-based agents have been widely used for cancer 
detection,98 brain imaging,99 and heart disease.100  
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1.4.4.2 T2 Shortening Agents  
T2 shortening agents are most often based on superparamagnetic iron oxide (SPIO) 
particles. Iron contrast agents also affect T1 and T2, though in this case the effect is more 
pronounced on T2, and thus it is usually visualized in T2- or T2*-weighted images.81 As 
SPIO particles are superparamagnetic with χ>>0 this produces local inhomogeneities by 
increasing the dephasing between protons, thus reducing the local T2 and T2*. This 
dephasing will make regions where SPIO is present appear as hypo-intense areas and, as 
the effect of inhomogeneity is large, it will extend over an area greater than the particle 
itself, making it easier to detect.81 This is a called a “blooming effect”. 
Clinically, SPIO-based agents are usually delivered by i.v. infusion and the enhancement 
lasts hours to days.101 SPIO-based agents are generally excreted through the liver.101 Iron 
oxide based contrast agents have been used clinically for liver imaging.102 T2-weighted 
images are acquired before and 24 hours after i.v. SPIO administration. Phagocytic 
Kupffer cells within the normal reticuloendothelial system (RES) will take up the i.v. 
administered iron, causing areas containing Kupffer cells to appear hypo-intense. In liver 
lesions, where no Kupffer cells are present, the signal will remain unchanged. 
Unfortunately the clinical grade SPIO-based agents have now been withdrawn from the 
market.  
 
1.5 Imaging The Spinal Cord Injury 
1.5.1 Clinical Use And Clinical Research 
Computed tomography (CT) is the standard imaging protocol for SCI.103 MRI is gaining 
popularity due to additional value in the cases of SCI without radiographic abnormality104 
and due to its high sensitivity to edema, hemorrhage and soft tissue damage, especially 
when no fracture occurs. However, it is not yet practical or cost effective across all 
institutions.105 Other spinal pathologies that have been observed clinically using MRI 
include extended atrophy106 and syringomyelia; thus, when possible and practical, MRI 
has shown value for management and prognosis making it the modality of choice.107, 108  
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Specialized MRI techniques continue to be developed for SCI assessment. Diffusion 
tensor imaging (DTI) has been used to examine SCI in greater detail than through 
anatomical MRI by using fractional anisotropy and apparent diffusion coefficients for 
nerve fibers tractography and correlating the data from MRI to motor function.109 
Susceptibility weighted imaging (SWI) has been used to detect small bleeds in SCI 
patients.110 As functional recovery is the goal for SCI management and therapies, tools to 
better understand function within the cord are also being developed such as functional 
MRI (fMRI), which is used to visualize neural activity and is being developed to monitor 
SCI and its responses to treatments.111 All of these MRI techniques were initially 
developed to study the brain and the translation to spinal cord imaging has not been 
without challenges specific to the cord, such as the relative size of the cord compared to 
the brain (as these techniques use large voxel sizes), and motion artifacts from breathing 
and CSF pulsation.  
In the cellular therapy research setting, MRI has been used to study changes in SCI in 
response to stem cell therapy. In a study where patients with a chronic SCI received HSC 
by direct transplant and i.v. infusion, MRI was used to exclude patients before the study, 
to assess complications following treatment, and to analyze whether there was cord 
thickening at the sites of atrophy after the treatment.57 In a different case, where fetal 
neural stem cells were transplanted by intracerebellar and intrathecal injections in a 
patient with ataxia telangiectasia, MRI was used to assess complications, which included 
a tumor in the spine. MRI of the spine was used for tumor monitoring, pre-surgical 
planning and follow-up after surgery.44  
1.5.2 Rodent MRI Of SCI 
As MRI use grows in the clinical setting, so it has in pre-clinical models. In order to 
assess potential therapies, it is imperative to be able to monitor the response to treatments 
in vivo, with longitudinal studies. Ohta et al. performed the first study where in vivo MRI 
findings at 2T were correlated to histological analysis using a cervical compression SCI 
rat model. They described areas of signal hypo-intensity in T2-weighted images due to 
hemorrhage, and areas of hyper-intensity 4 weeks after the injury that reflected edema, 
gliosis and cavity formation.112  Rodents are common models in SCI research; however, 
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their size relative to a human (e.g. 25g mouse, 300g rat, 80kg human) means that imaging 
technology needs to be able to achieve higher resolution in order to get good tissue 
visualization. In rat models, as animal-dedicated scanners operating at higher magnetic 
fields have become available they have been increasingly used for SCI research (e.g. 
7T113, 114). MRI has been used to compare SCI severities in a rat contusion model at 4.7T 
by assessing edema and lesion length.115 High-field MRI in SCI rat models has also been 
used to study syringomyelia at 9.4T,116 and to study cyst formation, hemosiderin 
deposition, edema and fibroglial scar in a rat contusion model of SCI at 17.6T.117  
 A recent study by Sandner et al. showed that high-resolution MRI could be performed at 
clinical field strengths (3T) in a rat contusion model allowing for GM/WM differentiation 
in the uninjured cord and hemorrhage, edema and cyst formation in SCI rats, which were 
correlated to histology.118 The authors discuss the advantages of using a clinical scanner, 
such as bore size, which they reported allowed for imaging of older and thus bigger rats 
without being limited in size, decreased mortality, since it allows for better ventilation, 
and availability. This study was followed up by a comprehensive description of the 
imaging techniques used to study CNS pathologies, including SCI, in rat models at 3T.119 
Additional imaging techniques continue to be developed for SCI assessment, including 
manganese enhanced imaging,120 magnetization transfer,121 DTI,114, 122 and fMRI.123  
Recently a comparison was made between mouse and rat SCI models using MRI (7T).124 
In vivo imaging of experimental disease models in the mouse spinal cord is particularly 
difficult because of the very small size of the cord itself (1.5mm2 in x-sec area)28 and the 
extreme curvature, which becomes more pronounced with SCI, besides the challenges 
associated with imaging SCI mice in vivo over time. These challenges include 
diminished thermal regulation, decreased breathing capacity, and deficits in 
cardiovascular function.125 In fact there have not been nearly as many studies in mouse 
SCI models as in rats especially with non-contrast enhanced anatomical MRI. There are 
only a few SCI mouse MRI in vivo studies using ultra-high magnetic fields (9.4T),126 
DTI (4.7 T127 and 9.4T128), manganese enhancement,129 and gadolinium enhancement at 
7T.124 More mouse cord studies have been done ex vivo130, 131 and only recently has the 
cord being imaged in vivo at a clinical field strength (1.5T).132 
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1.6 Cellular MRI 
Cellular MRI is a relatively young field of imaging which uses high resolution MRI along 
with contrast agents to study cellular events. The first studies appeared in the 90’s where 
iron-based contrast agents started to be used to label cells and be visualized through 
negative contrast enhancement in MRI133-135 and showed at those early stages great 
promise for future use of cellular MRI in disease and therapy. Iron oxide particles have 
been the most widely used contrast agent to label cells for detection by MRI. 
1.6.1 Cell Labeling  
In order to be able to detect cells with MRI, they must be labeled with a contrast agent. 
Most studies use one of two ways to label cells with iron particles, in situ or in vitro.  In 
situ labeling, also called ‘active labeling’, is performed by injecting iron particles into the 
bloodstream and is most often used to target circulating immune cells, or immune cells in 
inflamed tissues, which can phagocytose the particles.  
In vitro cell labeling is used mainly for cell tracking. To label cells in vitro the cells are 
co-incubated with the iron particles.  Many cell types will readily take up iron particles 
by simple co-incubation.  For example, macrophages, cancer cells and stem cells are 
relatively easy to label. Other cells, especially non-adherent cell types, are more difficult 
to label and require specialized techniques. Various methods have been developed to 
enhance the amount of iron taken up by cells. The use of transfection agents, such as 
poly-L-lysine, protamine sulfate, and lipofectamine, was one of the early methods 
demonstrated to improve uptake of iron particles.136 These compounds are positively 
charged and form complexes with the negatively charged iron particles through 
electrostatic interactions upon mixing prior to cell labeling. These complexes facilitate 
internalization of the iron particles into the cell membrane during labeling incubation.101 
One of the concerns in cell labeling is the fact that most protocols require long incubation 
periods, usually overnight, so a recent study assessed commercially available NH2 
functionalized iron particles and showed improved labeling efficiency in less than 4hrs in 
mouse embryonic fibroblasts, rat MSC, and rat BM-derived macrophages.137 
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Another method to improve uptake of iron particles is electroporation, also called 
magnetoelectroporation.136, 138, 139 In electroporation the cell membrane is temporarily 
disrupted allowing particles to move into the cell.  Walczak et al. developed this 
technique and used it to label neural mouse cells and human and rat MSC with iron 
internalization comparable to that achieved by traditional transfection agents without 
affecting cell viability, proliferation or differentiation capabilities, although labeling by 
electroporation requires careful optimization of parameters to avoid cell death.138 This 
technique has also been applied for leukocyte labeling.139 Other methods continue to be 
studied and developed to improve cell-labeling efficiency, like the use of magnetic fields 
and cell penetrating peptides.140 
1.6.2 Iron Particles 
1.6.2.1 Ultra-Small Superparamagnetic Iron Oxides (USPIO) 
Iron particles have traditionally been classified according to size. Ultra-small super-
paramagnetic iron oxides (USPIO) are particles with an iron core of approximately 5nm 
of maghemite (γFe2O3) and magnetite (Fe3O4) and a coating that can be made of dextran, 
citrate, carboxylmethyl-dextran, carboxydextran, or pegylated starch that brings the 
particle’s hydrodynamic diameter to roughly 10-50nm in size.141 Because of their small 
size these particles have a long circulation time and have been useful for labeling cells in 
situ in many animal models of inflammatory disease.142-145 USPIO has been used for 
atherosclerotic plaque models146 and continues to be developed for enzymatic 
activation.147 USPIO has also been used clinically for carotid artery plaque148 and lymph 
node imaging.149 Deserno et al. described how after i.v. injection, macrophages will take 
up the USPIO and carry them to the interstitial space, through the lymph vessels to the 
lymph nodes. If the tissue is healthy, USPIO-carrying macrophages will show up as areas 
of hypo-intensity, but in cancerous areas, where cancer cells will not take the USPIO and 
macrophages will not be able to occupy the same space, areas will seem brighter against 
the now darker background. This technique has been used for prostate, rectal, bladder, 
breast, head and neck cancer imaging.150 While USPIO has been used primarily for in situ 
labeling, it has also been used for in vitro cell labeling and cell tracking.  For example, to 
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track human adipose derived stem cells in a bone tissue engineering mouse model151 and 
human umbilical cord-derived MSC in the intact rodent brain.152 
1.6.2.2 Superparamagnetic Iron Oxides (SPIO) 
Standard superparamagnetic iron oxide particles (SPIO) have a similar core to USPIO, 
although slightly larger (7nm) coated with dextran, carboxydextran, starch, albumin or 
silicon153 with a hydrodynamic diameter of roughly 60-150nm.154 SPIO are the most 
commonly used iron agents for cellular MRI. They are used for both in situ and in vitro 
cell labeling. Using in situ labeling, the earliest method for cell tracking, SPIO has been 
used to detect and monitor inflammatory cells in animal models of multiple sclerosis,155 
SCI,96 arthritis,156 tissue rejection157 and atherosclerosis.158 The i.v. administration of 
SPIO was used extensively for clinical liver imaging159, 160 and it has also been used in 
clinical studies of atherosclerosis.161 In vitro labeling of cells with SPIO has been used 
for cell tracking in different animal models, for example to study distribution after i.v. 
injection of HSC,162 tissue rejection,163, 164 Parkinson’s disease models,165 and dendritic 
cell (DC) migration.166 SPIO has been used clinically for cell tracking in patients with 
melanoma (Netherlands),167 brain trauma (China),168 hypoxic brain injury (Poland),169 
diabetes (Switzerland170 and Czech Republic171), and one study that included multiple 
sclerosis (MS) and amyotrophic lateral sclerosis (ALS) (Israel).172 It should be noted that 
none of these studies have been performed in North America. 
1.6.2.3 Micron Sized Iron Oxides (MPIO) 
Micron-sized iron oxide agents (MPIO) are the largest particles.  These are basically 
plastic beads that were originally developed for cell sorting.  One type, Bangs beads 
(Bangs Laboratories, Fishers, IN) have a magnetite (Fe3O4) core encapsulated in a divinyl 
benzene/styrene polymer with a hydrodynamic diameter of >1µm (0.9-8 µm).  MPIO 
available from Chemicell have a core of 100-200nm of maghemite (γFe2O3) with a silica 
coating that brings its hydrodynamic diameter to 0.5µm, 0.75µm or 1.0µm (chemicell, 
Berlin, Germany).  MPIO can come dyed with a fluorescent tag and are inert.173  Both 
phagocytic and non-phagocytic cells readily endocytose the particles without the use of 
transfection agents and result in a higher iron content compared to cells labeled with 
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USPIO or SPIO.154 Because they are not biodegradable, MPIO have only been used in 
preclinical studies and only by a handful of imaging researchers.  
MPIO have typically been used for prelabeling of cells prior to their injection or 
implantation. Shapiro et al. showed that a single mouse hepatocyte labeled with MPIO 
could be detected in vivo with MRI. Other cells have been labeled in vitro with MPIO 
such as T-cells174 and macrophages.175  Our group has used MPIO for several years for in 
vitro cell labeling for tracking in models of glioma,97, 176 melanoma,177 metastasis,178, 179 
and DC migration.91 Recently Wu et al. have demonstrated that MPIO can also be used to 
label cells in situ in a rat cardiac rejection model180 and Foley et al. used the same 
technique for macrophage labeling in a mouse traumatic brain injury.181 In a slightly 
different approach for in situ labeling, endogenous neural progenitor cells were labeled 
by injecting MPIO directly into the lateral ventricle in the rat brain.182, 183 
1.6.3 Other Contrast Agents 
In recent years, Gd-based agents are being explored for cell tracking.184-187 The potential 
advantage of using Gd agents is the generation of positive contrast, rather than signal 
void, which addresses issues related to other sources of signal loss in MR images that can 
confuse image interpretation. However, the relaxivities of most Gd-based agents are 
much lower than iron-based labels and so the sensitivity is not as good and higher 
number of cells are needed for detection. Other examples of positive contrast agents 
being researched to label cells include manganese188 and fluorine-19 (19F).189  
1.6.4 Methods For Assessing Effects of Labeling 
It is important to assess cell viability, phenotype and function after in vitro labeling.136, 190 
A variety of methods can be used to measure the impact of labeling cells with iron 
particles.  These include: trypan blue exclusion for viability and cell proliferation by 
population doubling time and colony formation. Functionality can be assessed through 
many different assays.  Examples include the wound-healing (scratch) assay to evaluate 
migration; differentiation assays to assess osteogenesis, adipogenesis, and 
chondrogenesis; and gene expression profiling using micro-array analysis and 
quantitative polymerase chain reaction. 
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The majority of studies have reported no effect on the cells from iron labeling.136, 191, 192 
However, Soenen et al. have shown that too much iron will affect the cells by modifying 
the actin cytoskeleton which is involved in processes such as proliferation and 
apoptosis.193 In a study using USPIO labeled mouse ESC and MSC and rat multipotent 
adult progenitor cells Crabbe et al. reported that while differentiation was not affected, 
proliferation was changed.190 In another study Kostura et al. reported that SPIO inhibited 
differentiation into chondrocytes, but not adipocytes or osteocytes, in human MSC.194 In 
SPIO labeled DC, Dekaban et al. reported substantially reduced viability and changes in 
cell morphology at concentrations in excess of 400 mg/ml of SPIO.  Two recent papers 
describe the need for balancing of optimal cell labeling, for enhancing cell detection, and 
minimizing impact of iron on cell viability and function.195, 196 
1.6.5 Imaging Of Transplanted Cells 
MRI provides the opportunity to track these cells in vivo and may provide answers to 
matters such as optimal delivery route, overall distribution and trafficking to the organs 
of interest. Both iron197 and Gd-based198 agents have been used to image MSC in the 
CNS.  
1.6.5.1 MRI Of MSC Cellular Therapy In Preclinical Models  
There have now been several reports of imaging iron labeled MSC in disease models, 
these have included: infarcted heart rat models,199 lung metastasis, where MSC are being 
considered for their potential to deliver therapeutic agents,191 and different CNS models 
of disease such as middle cerebral artery occlusion, cortical photochemical lesions, and 
SCI.197, 200  
In SCI models, most cell tracking studies have been performed in rats. A couple of these 
imaging studies have come from the Sykova group and were performed on ex vivo cords. 
201, 202 They have shown that BM-derived MSC can be visualized as areas of signal loss at 
the lesion site at 4-5 weeks after transplant. Dunning et al. have used both SPIO and 
MPIO in vivo to label and track SC and OEC for up to 4 weeks in SCI rats. They also 
showed by histology that transplanted cells were remyelinating the demyelinated axons, 
demonstrating that the labeled cells retained their biological function and that the 
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majority of the label had remained within the transplanted cells.203, 204 Lee et al. tracked 
SPIO labeled OEC in rat SCI for 2 months and found that MRI was able to show that the 
OEC were unable to bridge the transection lesion.205 A couple of recent in vivo cell 
tracking studies have used a dual fluorescent/Gd-based label to track MSC in SCI rats 
and found that the distribution and migration of labeled MSC in SCI lesions could be 
tracked with MRI until 7 days after implantation on one study (though with a significant 
decrease in signal intensity after day 3),206 and up to two weeks in another.207 To the best 
of our knowledge there are no other published reports on cell tracking in a mouse model 
of SCI. 
1.6.5.2 MRI Of Cellular Therapy In Clinical Trials 
There have been a small number of clinical trials for cell therapy, which have used cell 
tracking with MRI. In the first study (Netherlands) De Vries et al.,167 monitored SPIO-
labeled DC after their intranodal injection into the lymph nodes of melanoma patients. 
While the injections were performed under ultrasound guidance by an experienced 
radiologist, MRI revealed that ~50% were failed injections, an important finding in the 
field of cell therapy. The other clinical MRI cell tracking studies have been in brain 
trauma (China),168 hypoxic brain injury (Poland),169 diabetes (Switzerland170 and Czech 
Republic171), MS and ALS (Israel),172 and last, but not least, one study in SCI (Brazil).208 
In this study, autologous HSC were labeled in vitro using MPIO coated with a CD34 
specific monoclonal antibody and injected in 10 patients with chronic SCI by lumbar 
puncture, while 6 patients received free MPIO. MRI showed areas of signal loss 20 days 
after transplantation in the patients that received labeled cells but not on the control 
patients. 
The lack of uniformity in cell types, labeling methods and imaging protocols make it 
difficult to compare between studies at this point. Nevertheless, both animal models and 
clinical trials have established that the ability to observe the overall distribution at 
different time points at the tissue or organ of interest, as well as the overall distribution, 
provides important information for cell therapy.  
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1.7 Rationale And Objectives 
SCI is a complex medical condition with no cure currently available. Cell therapy has 
emerged as a promising treatment for SCI due to the potential for MSC to differentiate 
into neural cells and, possibly more so, for their potential to exert immunomodulatory 
effects and trophic support of endogenous cells. Determining the fate of transplanted 
stem cells in vivo will be a critical component of trials for optimizing cellular therapies. 
MRI is capable of providing the spatial resolution and cell detection required to 
noninvasively monitor cells administered in SCI.   
Inflammation plays an important role in SCI.  Macrophages that infiltrate the injured cord 
tissue are known to have both beneficial effects, which will promote healing, and 
detrimental effects, which will exacerbate the injury. Progress has been made in 
understanding some of the mechanisms; however, there is still much to understand about 
the specific roles of these cells. Anti-inflammatory treatments aimed at reducing 
secondary injury due to inflammation in SCI would benefit tremendously from in vivo 
techniques for measuring cell numbers and spatial distribution and for monitoring 
changes in these parameters with treatment.  
The overall objective of this work was to investigate the use of cellular MRI to assess 
experimental SCI in vivo at 3T and to monitor the fate of transplanted MSC and the 
inflammatory response to SCI. 
Three specific objectives were undertaken. 
1. To image the normal mouse spinal cord in vivo using a 3T clinical whole-body 
MR system and to monitor the lesion in mouse traumatic spinal cord injury. 
(Chapter 2) 
2. To apply high-resolution cellular MRI technologies to follow MSC after 
transplantation in a traumatic SCI mouse model over time. (Chapter 3) 
3. To implement the techniques for imaging the macrophage response in vivo in rat 
SCI. (Chapter 4) 
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Chapter 2  
2 In Vivo Magnetic Resonance Imaging Of Spinal Cord 
Injury In The Mouse* 
Experimental models of spinal cord injury (SCI) are often performed in rodents with 
mouse models being increasingly utilized due to the recent availability of many 
interesting and valuable genetically modified mice.1-3 A variety of methods have been 
used to generate SCI in mice including clip compression, impactor devices and 
transections.4-7 SCI mice display a wound healing process that has not been seen in any 
other species.8 Understanding how SCI lesions develop and change over time in the mice 
is important for the design of new treatments aimed at promoting regeneration and repair.  
Currently, histopathology is the most commonly used method for evaluating 
experimental SCI. This traditional method is invasive, usually cross-sectional, labor 
intensive and provides only a “snapshot” of the overall pathology, especially for the 
spinal cord since it is practically impossible to section and analyze the cord in its entirety. 
Experimental studies of SCI would benefit greatly from imaging techniques that allow 
monitoring of the SCI dynamically in entire organs or animals.  
Magnetic resonance imaging (MRI) has several characteristics that make it effective for 
in vivo experimental studies of SCI. MRI can produce images with high spatial resolution 
and exquisite soft tissue contrast. Current micro-MRI techniques can achieve in vivo 
resolution on the order of tens of micrometers9, 10 and even higher resolutions, below 
5µm, have been reported in polymer bead phantoms11 and for imaging single cells in gel 
and water.12 MRI is non-invasive, nondestructive and three-dimensional (3D). Unlike 
histological analyses, MRI can provide a more dynamic view of changing pathology and 
cellular events in vivo.13-15 
                                                
*
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In Vivo Magnetic Resonance Imaging of Spinal Cord Injury in the Mouse 
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Journal of Neurotrauma. May 2009, 26(5): 753-762. doi:10.1089/neu.2008.0704. 
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In vivo MRI of experimental SCI is difficult, however, because of the very small size of 
the cord itself (1.5mm2 in cross-sectional area at the thoracic level8), the extreme 
curvature and the challenges associated with repeated imaging of diseased mice in vivo. 
As a result, there are only a few published reports of in vivo MRI studies of mouse cord 
injuries. In vivo anatomical imaging of the injured mouse cord has been accomplished 
using implantable radiofrequency coils,16 high field (9.4T, 11.75T), dedicated animal 
MRI scanners,17, 18 and manganese enhancement.19  
Cellular MRI is a newly emerging field of MR research that allows the “non-invasive and 
repetitive imaging of targeted cells and cellular processes in living organisms”.20 Cellular 
MRI requires that cells be labeled with MR contrast material to make them distinct from 
the surrounding tissues with magnetic iron nanoparticles being the preferred material.21, 22 
Areas containing iron-labeled cells appear as regions of signal loss on MR images, 
creating negative contrast.23, 24 In experimental cellular MRI, cells are typically loaded 
with magnetic particles prior to their injection or implantation.  The resulting signal 
hypo-intensities can be tracked in vivo providing information about the presence, location 
and migration of the iron-labeled cells.25-28 Various cell types have been tracked in vivo 
over several weeks and multiple cell divisions and with minimal impact on cell 
function.29-34 In 2006 we showed, for the first time, that even single iron-labeled cells can 
be visualized in vivo using MRI.35   
The use of cellular MRI to track transplanted stem cells has become a key area of cellular 
imaging research.36-39 Research aimed at visualizing transplanted cells in experimental 
diseases of the central nervous system (CNS) has provided good examples for the use of 
these tools. Some examples have included imaging of: iron-labeled neural stem cells 
transplanted into embryonic mouse brain,40 iron-labeled oligodendroglial progenitors 
transplanted into the ventricles of neonatal, myelin deficient rat brain,41 iron-labeled glial 
precursor cells transplanted as neurospheres into the ventricles of rats with experimental 
autoimmune encephalomyelitis,42 iron-labeled neural progenitor cells transplanted into 
the striatum of Parkinsonian mice43 and hematopoeitic progenitor and multipotent 
mesenchymal stromal cells (MSC) labeled with micron-sized iron oxide particles 
(MPIO).44 So far, nearly all studies have been of the ‘proof-of-principle’ type, 
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demonstrating that different types of iron nanoparticles and labeling strategies are useful 
for the non-invasive MR tracking of transplanted cells. There are no reports of in vivo 
cellular MRI being used to image the injured mouse spinal cord after transplantation of 
iron-labeled cells. Only a few studies have demonstrated the use of cellular imaging to 
monitor cell transplants after SCI and these have all been in rat models.45-47  
In this paper we demonstrated the use of high resolution MRI for the longitudinal 
anatomical imaging of SCI in the mouse. We also demonstrated, for the first time, the 
application of cellular MRI for the in vivo tracking of transplanted stem cells in the 
injured mouse spinal cord. 
 
2.1 Methods 
2.1.1 Animal Model 
All protocols for these experiments were approved by the University of Western Ontario 
Animal Care Committee in accordance with the policies established by the Canadian 
Council on Animal Care. 
For optimization of the MRI protocol healthy, uninjured (n=11) and SCI (n=14) C57/Bl6 
mice (Charles River Laboratories, Wilmington, MA, USA ) were used. Briefly, SCI was 
induced in 20-25g female mice at the level of the 4th thoracic (T4) vertebrae using a clip 
compression model.6 Mice were premedicated with atropine sulfate [0.05 mg/kg 
subcutaneously (s.c.); MTC Pharmaceuticals, Cambridge, ON, Canada] and placed on a 
heating pad to maintain body temperature. Surgical anesthesia was achieved using 
isoflurane USP (1.5% to induce and 1.25% to maintain; Abbott Laboratories, Saint-
Laurent, QC, Canada) in oxygen at a rate of 1 l/min, delivered through a nose cone. With 
the assistance of a surgical microscope, a laminectomy was performed to expose the T4 
segment of the spinal cord, as described by Joshi and Fehlings, and a FEJOTATM clip was 
used to compress the cord extradurally for 60 seconds, with a force of 8g. The muscles 
and the skin were closed with 4-0 Vicryl and the animals were allowed to recover under a 
heating lamp and then on a heated water pad. All animals were treated with 
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buprenorphine (0.1 mg/kg s.c.; Temgesic, Schering-Plough, Hertfordshire, UK) as 
needed and 5 mg/kg of Baytril (Bayer, Toronton, ON, Canada) and 0.5ml (1ml on the day 
of surgery) of 0.9% saline twice daily for 3 days. Bladders were voided twice daily by 
manual compression.  
2.1.2 Transplantation Model 
Whole bone marrow was acquired from the femurs of 3-6 month old mice and plated 
onto T-25cm2 tissue culture flasks (BD Falcon™, Mississauga, ON, Canada) by 
adherence. 5ml of Dulbecco/Vogt modified Eagle's minimal essential medium (DMEM) 
with 10% fetal bovine serum (FBS), 2nM L-glutamine, 100 units/ml penicillin and      
100 µg/ml streptomycin were added and cells were kept at 37ºC in 5% carbon dioxide. 
Non-adherent cells were removed and cells were passaged with fresh medium (1:3 
dilution) until reaching 80% confluency. MSC were characterized by flow cytometry 
using antibodies raised against a battery of markers at passage four, including c-kit, 
CD11b, CD31, CD34, CD45 and relative isotype controls. 
In order to be able to detect the donor MSC with MRI they were labeled with iron.48-50 
The cells were washed with Hank's balanced salt solution (HBSS; GIBCO®, 
Invitrogen™, Burlington, ON, Canada) and incubated for 24hrs at 37ºC in 10ml of fresh 
DMEM containing 10µl of magnetic silica particles (SiMAG, 0.75µm; chemicell, Berlin, 
Germany). The trypan blue exclusion and plating efficiency assays were performed to 
examine potential effects of iron oxide particles on cell functions and viability.  
At day 2 post SCI, 3 x 104 MSC were transplanted into the injured mice. An intra-spinal 
transplant was performed by excising the dura at the epicenter of the SCI (T4 level). 
Using a spinal stereotaxic frame, 3x104 cells in 3µl of saline were transplanted with a 
glass pipette (tip diameter=100µm) configured to a 10µl Hamilton syringe51 (n=13 
received labeled cells, n=3 received unlabeled cells). 
2.1.3 Magnetic Resonance Imaging 
Imaging was performed using a 3 Tesla (3T) GE whole-body MR scanner (MR Signa® 
Excite™, GE Healthcare, Milwaukee, WI, USA ) using a custom-built gradient coil (inner 
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diameter=17.5cm, maximum gradient strength=500 mT/m, and peak slew rate=3000 
T/m/sec). Mice were anesthetized with isoflurane (2%) and placed on a custom-built 
plastic sled to permit careful and reproducible positioning to allow sagittal imaging of the 
cord. The sled was positioned within a custom-built solenoid radiofrequency (RF) coil 
(the antenna of the MR system), which is 4cm in length and 3cm in diameter, allowing 
for the acquisition of whole mouse body images. The lower part of the body and tail were 
wrapped using gauze to maintain body temperature.52  Mice were scanned using a 3D 
balanced steady state free precession (bSSFP) pulse sequence (3D-FIESTA; GE Medical 
Systems, Milwaukee, WI, USA ; TR/TE=3.8/1.8ms, α=25º) at a 200µm isotropic 
resolution with 16 NEX and employing RF phase cycling. Acquisition time was 31min. 
Mice recovered under a heating lamp. SCI mice were imaged weekly for up to 6 weeks.  
Transplanted mice were imaged at day 2 after the transplant and then weekly for up to 6 
weeks. 
2.1.4 Image Analysis 
Image quality was assessed by calculating the image signal to noise ratio (SNR). The 
mean signal intensity in a region of interest in the spinal cord was divided by the standard 
deviation of the background noise in air.  Images of injured cords were assessed for 
changes in signal intensity at the lesion epicenter. 3D image data allowed for an analysis 
of patterns of image contrast in all orientations. Images of transplanted mice were 
assessed for regions of signal loss due to the presence of iron-labeled cells. The regions 
of interest were measured by manual segmentation using the open-source imaging 
software OsiriX.53 
2.1.5 Histopathology 
After the final imaging session the mice were induced with deep anesthesia, and 
transcardially perfused with 4% paraformaldehyde (PFA) in 0.1M phosphate buffer. The 
spinal cords were removed and placed in phosphate buffer containing 20% sucrose at 4ºC 
overnight. Cord tissue was sagittally sectioned on a cryostat set at 16µm. The sections 
were serially collected on gelatine-coated glass slides and subsequently stained with 
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standard hematoxylin and eosin (H&E) techniques for visualization of the cord and lesion 
morphology, and with Perls’ Prussian blue (PPB), for visualization of the iron particles. 
2.2 Results 
2.2.1 Anatomical Imaging 
3D-bSSFP mouse cord images were obtained at 3T with a cord SNR of approximately 
50. Representative in vivo images from a control, intact mouse are shown in Figure 2.1.   
 
Figure 2.1: In vivo high-resolution (200µm isotropic) MR images of a mouse spinal 
cord using 3D–bSSFP (TR/TE=3.8/1.8ms). (a) Sagittal view of a healthy uninjured 
mouse in the prone position with the head to the right. Scale bar=5mm. (b) Cord axial 
views can be reconstructed by digital reslicing of the 3D image data, in a tilted plane 
(dashed line in a) to compensate for the natural curvature of the mouse spine. Scale bar=2 
mm. 
In all SCI mice the injury appeared as a region of heterogeneous signal, which included 
areas of both signal hyper-intensity and signal loss. Figure 2.2 shows four images, 
acquired at different time points, from a representative SCI mouse; the long arrows 
indicate the lesion epicenter. In this mouse the lesion appears subtle for up to 1 week post 
SCI (Fig. 2.2a).  Over time, as the lesion evolved, signal loss became more apparent at 
the epicenter. At 4 weeks post SCI (Fig. 2.2c) a more distinct region of signal loss at the 
lesion epicenter defines the lesion more clearly.  The signal loss was evident in the 
majority of mice by 2 weeks post SCI, and in all cases persisted for the 6 weeks of the 
study. In addition, the area surrounding the cord tissue, which contains the cerebrospinal 
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fluid (CSF), which appears very bright in the images (short arrows, Fig. 2.2b), was larger 
in all SCI mice compared to control, uninjured mice. 
 
Figure 2.2: Representative in vivo sagittal spinal cord images. Here the same animal is 
shown at different time points after SCI: (a) 1 week, (b) 2 weeks, (c) 4 weeks, and (d) 6 
weeks. The epicenter of the injury (long arrows) appears as a region of heterogeneous 
signal at 1 week. By 4 weeks, a region of signal loss appears obvious at the lesion 
epicenter. The area surrounding the cord and containing the CSF, which appears with 
high signal intensity (short arrows), is enlarged in SCI mice. 
Of particular interest was the observation of fluid filled lesions in 3/16 mice.  These cyst-
like lesions were rostral to the epicenter of the injury (up to 8mm away), they were first 
observed as early as 2 weeks post SCI, and they increased in size with time. Figure 2.3 
shows representative sagittal (Fig. 2.3a) and axial (Fig. 2.3b) images of a SCI mouse cord 
at 3 weeks post SCI with this fluid filled lesion, in this image the lesion was 0.73mm3. 
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This lesion was first observed at 2 weeks and measured 0.36mm3. By the end of the 
study, at 6 weeks, the lesion measured 1.05mm3.  Cyst-like lesions in the other two 
animals also increased in volume over time. 
 
Figure 2.3: A fluid-filled, cyst-like lesion is visible rostral to the lesion epicenter. The 
cyst volume increased in size over time from when it was first observed at 2 weeks (a, 
arrow, 0.36mm3) to the end of the study at 6 weeks (b, 1.05mm3). (c) The axial view is 
shown at the level indicated by the dashed line in b. 
2.2.2 Cellular Imaging of Transplanted MSC 
The trypan blue exclusion assay showed that 100% of both labeled and unlabeled cells 
were viable after harvesting.  Plating efficiency results showed for labeled and unlabeled 
cells an efficiency of 74% and 95% respectively (each from an average of six plates).  
The average iron content was found to be 83.65pg Fe/cell.  
Representative images of an injured mouse transplanted with iron-labeled MSC are 
shown in Figure 2.4. A large region of signal loss was observed at the site of the 
transplant on day 2 post transplant (arrows, Fig. 2.4a). The region of signal loss persisted 
over the 6 weeks of the experiment but diminished in size with time. Similar observations 
were made in 9 of the 13 SCI mice that received iron-labeled MSC transplants. The total 
void volume measured on the first scanning session was different for each animal, despite 
having implanted the same numbers of MSC, likely due to both small differences in the 
implantation procedure and differences in cell survival between the implant and the first 
scan. The 3D image data allowed for image rendering and 3D reconstruction. A single 
frame from the reconstructed image data is shown in Figure 2.4d and clearly depicts the 
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extreme curvature of the injured cord and the location of the transplanted MSC (red) at 1-
week post transplant.  
 
Figure 2.4: Representative in vivo images of the injured mouse spinal cord after 
transplantation of iron-labeled MSC. A large region of signal loss (arrows) is easily 
visualized at the site of transplantation and diminishes over time during 6 weeks of 
scanning post-transplant (shown counterclockwise). The volume of the region of signal 
void for this representative mouse was 6.76mm3 on day 2 post-transplant (a), 5.47mm3 
on week 2 (b), and 4.21mm3 on week 5 post-transplant (c). (d) A single still frame of the 
same mouse spinal cord is shown after segmentation and 3D rendering of week 1 image 
data (6.12mm3). The site of transplantation is shown in red. The mouse body has been 
segmented out of the image data to allow better visualization of the cord. 
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Measurements of the volume of the signal loss in the cord showed a reduction with time 
in all animals (Figure 2.5).  
 
Figure 2.5: Volume of the region of signal loss in the cord for all mice. Each symbol 
represents one of the nine mice that showed regions of signal loss following the 
transplant of labeled MSC. 
In Figure 2.6 PPB staining shows iron labeled cells in the injured mouse cord at 6 weeks 
post cell implantation. At the lesion epicenter (Fig. 2.6 a&b) there are greater numbers of 
iron positive cells (blue), though the cells are not limited to the epicenter and can be seen 
away from the epicenter at a lower concentration. Figure 2.6 c&d show iron labeled cells 
in a section approximately 1mm caudal from the lesion epicenter.  
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Figure 2.6: Staining with PPB showed iron-labeled cells at 6 weeks post-transplant. At 
the lesion epicenter, there is a higher concentration of iron-positive cells (blue, 40x 
magnification, a,b). Iron-labeled cells are also present, at a lower concentration, 1mm 
caudal from the lesion epicenter (10x magnification, c). The region of interest outlined in 
c  is shown in d at higher magnification, iron is intracellular (d). 
Figure 2.7 shows representative images of the cord in a SCI mouse that received a 
transplant of unlabeled MSC.  These images appeared very similar to the images of SCI 
mice that received no cell transplant (shown in Figure 2.2). The lesion is subtle in images 
acquired during the first week post transplant with small regions of signal loss developed 
by 3 weeks post transplant.  
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Figure 2.7: In vivo images of the injured mouse spinal cord after transplantation of 
unlabeled MSC. As in SCI mice that received no transplant, the lesion epicenter is not 
obvious in the first week post SCI. (a&b) Images acquired at 2 days and 1 week post-
transplant (epicenter indicated by arrows). (c) At 3 weeks, areas of signal loss are 
observed rostral and caudal to the epicenter (arrow). (d) The signal loss in these areas 
became even more evident by week 6. 
 
2.3 Discussion 
Key to our success was the use of a fast, 3D imaging sequence. The bSSFP sequence is 
known to yield a high SNR in short acquisition times and to generate T2/T1 contrast.54, 55 
It is also very sensitive to the local magnetic field variations caused by iron particles. 
This sensitivity to local field variations has also be known to cause characteristic banding 
artifacts56 which become worse with increasing field strength,57 and thus has limited the 
application of this imaging sequence for preclinical mouse imaging.  We have previously 
imaged the mouse brain at 1.5 and 3T with bSSFP.35, 58, 59 Banding artifacts, which were 
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pronounced at 3T, were suppressed by the combination of alternating RF phase 
acquisitions and sum of squares reconstruction.  Recently Miraux et al. showed that this 
strategy also allows the application of this sequence for mouse brain imaging at 4.7 and 
9.4T.60  The work presented here was the first application of this imaging strategy for 
imaging the mouse body, which presents added challenges because there are multiple 
additional sources of magnetic field inhomogeneities in the body (air in lungs, intestines, 
bone, numerous fat-tissue interfaces) that may disintegrate image quality. bSSFP images 
of the injured mouse spinal cord showed a heterogeneous signal at the lesion epicenter 
with areas of both signal hyper-intensity and signal hypo-intensity, representing the 
mixed pathology present in the injured cord.  This is similar to what has been previously 
reported by Bilgen et al. in mice with a contusion SCI.18  
The areas of signal loss in cord images of mice that did not received a transplant or 
received unlabeled MSC may be due to the accumulation of hemosiderin-laden 
macrophages, associated with hemorrhage breakdown. Bilgen et al. reported that signal 
loss in MR images of the injured rat cord was due to hemorrhage.18 Lee et al. showed that 
needle injury to the rat spinal cord during a cell transplantation procedure produced 
signal loss in rat cord images that could be attributed to hemosiderin-positive cells.47 
Alternatively, signal loss in the SCI lesion may be due to the generation of fibrous 
connective tissue which has been shown to fill the lesion site in mice.8 In fact, both of 
these pathological processes may be evident in the injured mouse cord and contributing 
to signal hypo-intensities.  
Whatever the source, signal loss in the images of the injured mouse cord may complicate 
the interpretation of images in MRI cell tracking studies which use iron as the cell label 
and signal loss as the indicator of cells. Distinguishing hypo-intensities due to iron-
labeled cells from other causes of negative image contrast, might be solved by using 
positive (gadolinium-based) contrast agents for cell labels.61 The development of new 
pulse sequences which generate positive contrast from iron-labeled cells, which is 
underway, may also alleviate this concern.62, 63 Alternatively one might acquire two 
different image contrasts and compare images to differentiate sources of signal loss, as 
Kusterman et al. did using T2* and proton density-weighted images to differentiate iron-
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labeled cardiomyocytes from the infracted myocardium, which also appeared as signal 
loss.36   
Most reports in the current literature suggest that while rats and other mammals develop 
fluid-filled cysts after SCI, mice do not.8, 64, 65 Micro-cysts have been reported in mice, 
but not central cavities,6, 66 and moderate cavities have been reported in mice using a 
displacement contusion model.66 In our experiments, MRI revealed the presence of large 
cystic lesions rostral to the epicenter of the SCI, at a distance much farther than is 
typically interrogated by histology.  The 3D image data allowed the volume of these cysts 
to be calculated. The cyst volume increased with time for each of the 3 animals in which 
this pathology was observed. The cysts that we observed resemble what has been 
described in the literature as post-traumatic syringomyelia,67 a relatively rare 
complication secondary to SCI68 which is not fully understood.   
In this paper we also presented initial results of in vivo stem cell tracking in mouse SCI, 
the first of its kind. In the past few years MSC have been explored as an option to 
promote functional recovery after SCI in the rat69, 70 and the mouse71 and their role in 
neurogenesis and functional recovery in a non-human primate SCI model was studied 
with encouraging results.72 While there are still many questions remaining on the topic of 
stem cell engraftment, MSC represent a promising option for cell therapy following SCI 
and cellular MRI may play an important role in answering these questions. 
We applied our microimaging technology to monitor the fate of iron-labeled MSC after 
their implantation directly into the injured mouse cord.  The presence of the cells in the 
cord was easy to recognize as a large localized region of signal loss and could be 
monitored over time in vivo.  The volume of the signal void could be measured and was 
found to diminish in size with time. This cellular imaging technology will allow us to 
study factors that influence stem cell survival and engraftment by providing 3D in vivo 
image data at multiple time points, post cell transplantation under various conditions.  
Future work in our lab will expand on this pilot study of MSC tracking with a focus on 
validating the ability of MRI to accurately detect and monitor iron labeled cells and on 
comparing MRI results with locomotor outcomes. 
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An additional concern, and potential limitation of tracking iron labeled cells with MRI, is 
that free iron, that might be released from dead or dying MSC, may be mistakenly 
reported as viable cells.  Or, that iron released from dead cells might be taken up by 
macrophages and similarly be incorrectly identified as viable MSC. Previous cell tracking 
studies have shown that with the rejection of cells, as an example, after transplantation 
into the liver, regions of signal loss disappear within days, as they are cleared by resident 
Kupffer cells.73 A recent paper by Pawelczyk et al., which studied iron uptake by 
bystander cells in an in vitro model system, indicates that the transfer of iron particles to 
macrophages, from dead, iron- labeled cells, accounts for <10% of the total iron in the 
labeled cells.74  These data advocate caution, since the implantation of iron-labeled cells 
into tissues can result in uptake of label by macrophages, but also, suggest that the 
amount of iron in these cells may quite low and that iron particles will be degraded 
relatively quickly.  
In conclusion, these results demonstrate the potential of in vivo MRI for detecting and 
monitoring the pathology associated with spinal cord injuries in mice and for tracking the 
fate of transplanted stem cells. The ability to follow SCI noninvasively in mice will 
permit the evaluation of various treatments. MR tracking of transplanted cells may 
become a powerful tool for understanding the mechanisms that are responsible for the 
successful migration, survival and expansion of transplanted cells in vivo. 
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Chapter 3  
3 The Use Of Cellular Magnetic Resonance Imaging To 
Track The Fate Of Iron-Labeled Multipotent Stromal Cells 
After Direct Transplantation In A Mouse Model Of Spinal 
Cord Injury† 
Labeling cells with iron particles allows for their detection by magnetic resonance 
imaging (MRI). This imaging approach has been used to detect and track a variety of cell 
types in a number of different animal models of disease.1-8 Areas containing iron-labeled 
cells appear as regions of low signal intensity on MRI images, creating negative 
contrast.9 Research aimed at visualizing transplanted cells in experimental diseases of the 
central nervous system (CNS) has provided good examples for the use of these tools.10-16 
So far, nearly all studies have been of the ‘proof-of-principle’ type, demonstrating that 
various types of superparamagnetic iron particles and labeling strategies are useful for the 
long-term non-invasive MR tracking of transplanted cells. 
Spinal cord injury (SCI) is an example of a difficult neurological problem with limited 
therapeutic options, where stem cells have renewed hope that repair and recovery from 
CNS trauma is possible.17-21 Recent reports show that several types of stem cells can be 
induced to differentiate into neural cells.22, 23 A variety of cell types have been used as 
transplants in SCI, including cells normally associated with inflammatory reactions, that 
is: macrophages,24, 25 T-cells,26 and dendritic cells;27 and cells with stem cell properties: 
namely embryonic stem cells,28 neural stem cells (NSC),29 bone marrow derived 
multipotent mesenchymal stromal cells (MSC)30-33 and, hematopoietic stem cells.18 
                                                
†
 A version of this chapter has been published and is used here with kind permission from Springer 
Science+Business Media: Molecular Imaging and Biology, The Use of Cellular Magnetic Resonance 
Imaging to Track the Fate of Iron-Labeled Multipotent Stromal Cells after Direct Transplantation in a 
Mouse Model of Spinal Cord Injury, Vol. 13, 2011, p. 702-711, Laura E. Gonzalez-Lara, Xiaoyun Xu, 
Klara Hofstetrova, Anna Pniak, Yuhua Chen, Catherine D. McFadden, Francisco M. Martinez-
Santiesteban, Brian K. Rutt, Arthur Brown, Paula J. Foster, Figures 3.1-3, 3.5, 3.9-10, 3.12 ©Academy of 
Molecular Imaging and Society for Molecular Imaging, 2010 
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Remarkably, all of these paradigms improve recovery after SCI, suggesting that some of 
the effects are independent of the source of donor cells.  
Stem cells have been administered to SCI patients.34-38 Moviglia et al. have performed a 
preliminary study of the intra-arterial transplantation of autologous NSC in two patients 
without adverse effects.36 Two other groups have evaluated the effect of autologous bone 
marrow derived stem cells transplanted into both the injury and intravenously (i.v.).34, 35 
Still, many important questions persist relating to the best protocols for delivering 
adequate numbers of stem cells. For example, there is no official consensus on the best 
route of administration or the optimal number of stem cells to be administered. Central to 
the future success of cell transplantation is the ability to noninvasively assess the fate, 
migration patterns and survival of transplanted cells.  The use of MRI for tracking stem 
cells after their administration can provide a more dynamic view of cellular events in 
vivo and should provide insights into many basic and practical questions regarding cell 
therapies that can be directly translated into human clinical applications. 
A potential limitation of tracking iron labeled cells with MRI is the possibility of transfer 
of the label to local bystander cells (i.e. macrophages) potentially confusing the 
interpretation of viable transplanted cells in the images. Terrovitis et al. reported that 
signal loss in MR images persisted for three weeks after cardiac transplant, while 
histology at three weeks showed only iron labeled macrophages at the transplant site, and 
few or no viable stem cells.39 Additional studies are required to know whether the 
transfer of iron labels is particular to certain transplant protocol, or to specific types of 
injury or disorder, and whether long-term cell tracking by MRI using magnetic particles 
is out of the question, or only something we need to be sensitive to when interpreting our 
data.  Here we report on a study where MSC labeled with micron sized iron oxide 
particles (MPIO) were administered by direct transplant in a mouse model of SCI and 
monitored in vivo for 6 weeks by MRI.  
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3.1 Materials and Methods 
3.1.1 Animal Model 
All protocols for these experiments were approved by the University of Western Ontario 
Animal Care Committee in accordance with the policies established by the Canadian 
Council on Animal Care.  
A clip compression SCI was induced in C57/Bl6 (n=17) and K15-EGFP (n=16) 20-25g 
female mice at the 4th thoracic (T4) level, as it has been previously described.40 Mice 
were premedicated with atropine sulfate (0.05 mg/kg s.c.; MTC Pharmaceuticals, 
Cambridge, ON, Canada) and placed on a heating pad to maintain body temperature. 
Surgical anesthesia was achieved using isoflurane USP (1.5% to induce and 1.25% to 
maintain; Abbott Laboratories, Saint-Laurent, QC, Canada) in oxygen at a rate of 1 l/min, 
delivered through a nose cone. With the assistance of a surgical microscope, a 
laminectomy was performed to expose the T4 segment of the spinal cord, as described by 
Joshi and Fehlings,41 and a FEJOTATM clip was used to compress the cord extradurally 
for 60 seconds, with a force of 8g. The muscles and the skin were closed with 4-0 Vicryl 
and the animals were allowed to recover under a heating lamp and then on a heated water 
pad. All animals were treated with buprenorphine (0.1 mg/kg s.c.; Temgesic, Schering-
Plough, Hertfordshire, UK) as needed and 5 mg/kg of Baytril (Bayer, Toronto, ON, 
Canada) and 0.5ml (1ml on the day of surgery) of 0.9% saline twice daily for three days. 
Bladders were voided twice daily by manual compression.  
3.1.2 Transplantation Model 
Bone marrow derived MSC were transplanted into SCI mice. The donor strain 
(Tg(ACTBEGFP)1Osb), expresses enhanced green fluorescent protein (EGFP) under the 
control of the chicken beta-actin promoter and cytomegalovirus enhancer in all tissues, 
with the exception of erythrocytes and hair.42  One of the recipient strains, K15-EGFP, 
expresses EGFP under the direction of the mouse keratin complex 1, acidic, gene 15 
promoter. This promoter limits EGFP expression to the hair follicles in the skin.43 These 
mice are the ideal donor-recipient pair as these transgenics were generated on the same 
genetic background, C57Bl6, which we used as our other recipient strain. Hence the 
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transplants should be fully compatible with the hosts and easily detected by their 
expression of EGFP.  
Whole bone marrow was acquired from the femurs of 3-6 month old male mice and 
plated onto T-25cm2 tissue culture flasks (BD Falcon™, Mississauga, ON, Canada) by 
adherence. The flask contained 5ml of Dulbecco/Vogt modified Eagle's minimal essential 
medium (DMEM) with 10% fetal bovine serum, 2mM L-glutamine, 100 units/ml 
penicillin and 100 µg/ml streptomycin and cells were kept at 37ºC in 5% carbon dioxide. 
Twenty-four hours after cultured, non-adherent cells were removed and once adherent 
cells reached 80% confluence they were passaged with fresh medium (1:3 dilution) every 
2-3 days. MSC were characterized by flow cytometry using antibodies raised against a 
battery of markers at passage four, including c-kit, CD11b, CD31, CD34, CD45 and 
relative isotype controls. 
To label cells with MPIO for MRI detection, they were plated at a concentration of 8x104 
c/ml in DMEM.  The cells were labeled using 10µl of magnetic silica particles (SiMAG, 
0.75µm; chemicell, Berlin, Germany) and incubated for 24hrs at 37ºC in 5% CO2.  Cells 
were then washed with Hank's balanced salt solution (HBSS; GIBCO®, Invitrogen™, 
Burlington, ON, Canada) three times and trypsinized using 0.25% Trypsin-EDTA 
solution.  Three additional washes with HBSS were performed before counting the cells.  
Trypan blue exclusion and flow cytometric assays were performed to examine potential 
effects of iron oxide particles on cell viability and functionality. The trypan blue 
exclusion assay was performed after labeling the cells both before and after passing the 
cells through the needle, to assess the effect of the injection process on the cells. For flow 
cytometry, after harvesting, cells were resuspended in 1xBinding Buffer to a 
concentration of 106 c/ml and 100µl aliquots were prepared for each sample. Tubes 
contained either 5µl of Annexin V-APC (Allophycocyanin), 7-AAD-PE (7-
Aminoactinomycin D conjugated with Phycoerythrin), or both. These samples were 
incubated for 15min at room temperature in the dark and then run through a 50µm filter 
with 400µl of 1xBinding Buffer into a new tube. Cytospin slides with 2x105 labeled or 
unlabeled cells were stained with Perls’ Prussian Blue (PPB) to confirm the presence of 
iron and eosin to stain for cytoplasm. 
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Labeled and unlabeled cells were harvested and placed in 5ml of fixative solution, 2.5% 
gluteraldehyde in 0.1M sodium cacodylate buffer.  The sample was spun down and 
resuspended in 1ml of 0.1M cacodylate buffer before being washed, enrobed in 5% noble 
agar, washed again and fixed in 2% uranyl acetate.  Afterward it was dehydrated with 
ethanol.  The sample was then infiltrated with varying concentrations of epon resin to 
propylene oxide and embedded in polymerize resin.  Finally, the sample was cut into thin 
(60-90nm) sections and placed on formvar/carbon film 300 mesh grids to view with 
transmission electron microscopy (TEM).  
The dura was excised at the epicenter of the SCI (T4 level) for an intra-spinal transplant. 
Using a spinal stereotaxic frame, 3x104 cells in 3µl of saline were transplanted with a 
glass pipette (tip diameter=100µm) configured to a 10µl Hamilton syringe.44 Five groups 
of SCI mice were used.  Group 1 (n=18) received 3 x 104 MPIO-labeled MSC within one 
week after SCI. Group 2 (n=4) received 3 x 104 MPIO-labeled MSC that had been treated 
with sodium nitroprusside (1mM) prior to transplantation to induce apoptosis, Group 3 
(n=4) received MPIO particles equivalent to the iron content in 3 x 104 cells (0.83 mg/ml) 
diluted in saline, Group 4 (n=3) received 3 x 104 unlabeled MSC, and Group 5 (n=4) did 
not have a transplant. 
3.1.3 Magnetic Resonance Imaging 
Mice were imaged using a 3 Tesla (3T) GE whole-body MR scanner (MR Signa® 
Excite™, GE Healthcare, Milwaukee, WI, USA ) using a custom-built gradient coil (inner 
diameter=17.5cm, maximum gradient strength=500 mT/m, and peak slew rate=3000 
T/m/sec). Mice were anesthetized with isoflurane (2%) and placed on a custom-built 
plastic sled to permit careful and reproducible positioning to allow sagittal imaging of the 
cord. The sled was positioned within a custom-built solenoid radiofrequency (RF) coil, 
which is 4cm in length and 3cm in diameter, allowing for the acquisition of whole mouse 
body images. The lower part of the body and tail were wrapped using gauze to maintain 
body temperature.45 Mice were scanned using a 3D balanced steady state free precession 
(bSSFP) pulse sequence (3D-FIESTA; GE Medical Systems, Milwaukee, WI, USA ; 
TR/TE=3.8/1.8ms, flip angle=25º, 4cm x 2.4cm FOV, 128 locs per slab) at 200µm 
isotropic resolution with 16 NEX and 2 RF phase cycles. Acquisition time was 31 min. 
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Mice recovered under a heating lamp. SCI mice were imaged on day 0, day 2 and 1, 2, 
3/4 and 6 weeks post transplantation. 
3.1.4 Image Analysis 
Images of injured cords were assessed for changes in signal intensity at the lesion 
epicenter. 3D image data allowed for an analysis of patterns of image contrast in all 
orientations. Images of transplanted mice were assessed for regions of signal loss due to 
the presence of MPIO-labeled cells. The volume of these regions was measured by 
manual segmentation using the open-source imaging software OsiriX.46 The volume for 
the region of signal loss for each animal was normalized to day 2. Volumes were 
measured for each time point, averaged for each group separately and the standard error 
of the mean (SEM) was calculated for each group. Two independent observers measured 
the volumes of the regions of signal loss for all animals for each time-point, for at least 4 
weeks. Inter-observer variability in volume measurement was assessed using analysis of 
variance (ANOVA).  
3.1.5 Histology 
After the final imaging session the mice were induced with deep anesthesia and 
transcardially perfused. The spinal cords were removed and placed in phosphate buffer 
up a sucrose gradient (10%, 20%, 30%) at 4°C. Cord tissue was sagittally sectioned on a 
cryostat set at 16µm. The sections, which were 6-8mm in length with the lesion epicenter 
in the middle of the section, were serially collected on gelatine-coated glass slides, 
alternating between two slides resulting in adjacent sections with different stains. For 
each animal approximately one third of the slides was stained with PPB, for visualization 
of the iron particles, and nuclear fast red for visualization of the cord and lesion 
morphology. A second portion of the slides was stained with anti-GFP, IgG, Alexa 
Fluor® 488 conjugate (Invitrogen; Eugene, OR, USA ) to highlight the EGFP+ MSC. 
Finally, the third portion of the slides was stained with Biotin Anti-Mouse Macrophage 
(F4/80) Monoclonal Antibody  (CEDARLANE Laboratories Ltd.; Burlington, ON, 
Canada) and TSA™ (Tyramide signal amplification) Biotin (PerkinElmer; Woodbridge 
ON, Canada) to identify macrophages. VECTASHIELD® HardSet™ Mounting Medium 
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with DAPI (Vector Laboratories Inc.; Burlingame, CA, USA ) was used to identify the 
nuclei using fluorescence.  Stained sections were visualized using optical or fluorescence 
microscopy with a Zeiss AXIO Imager (Carl Zeiss Canada Ltd.; Toronto, ON, Canada).  
 
3.2 Results 
3.2.1 Cell Labeling 
In TEM images the iron core of the MPIO particles could be detected within endosomes 
in the cell cytoplasm of the labeled MSC (Fig. 3.1 a&b). PPB staining also showed that 
the iron particles were located within the cells (Fig. 3.1c). Labeling MSC with MPIO did 
not affect cell viability; the trypan blue exclusion assay showed that 94% of labeled and 
98% of unlabeled cells were viable after harvesting (Fig. 3.1d) (from an average of 4 
samples for each) and that 89% of the labeled cells were viable after passing through the 
needle used for transplantation.  
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Figure 3.1: Mouse MSC labeled with MPIO. In electron microscope images, the iron 
cores of the MPIO particles appear as dark clusters contained within endosomes (a and b, 
arrows). PPB staining shows the iron particles (blue) within the cells (c). A trypan blue 
exclusion assay showed that labeling MSC with MPIO did not affect cell viability; 94% 
of labeled and 98% of unlabeled cells were viable after harvesting (d). 
Representative Annexin V/7-AAD flow cytometry dot plots for unlabeled (control) and 
MPIO-labeled MSC are shown in Figure 3.2. There was no statistically significant 
difference in the numbers of unlabeled or MPIO labeled cells that were nonviable (7-
AAD) or apoptotic (Annexin V).  
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Figure 3.2: Flow cytometric analysis of viability in MPIO-labeled and unlabeled MSC. 
Top panel shows results of Annexin V binding. The Annexin-V-positive population 
contains early apoptotic cells. The bar graph shows the mean percentages of Annexin-V-
positive cells+standard deviation. There was no significant difference in the percentages 
of Annexin-V-positive cells for unlabeled (10%) or MPIO-labeled (13%) MSC (n=3 
each). Representative dot plots for Annexin V are also shown for one sample where (a) 
and (b) indicate the percentages of live and apoptotic cells, respectively. Bottom panel 
shows results of 7-AAD permeability. The 7-AAD positive population contains 
nonviable cells. The bar graph shows the mean percentages of 7-AAD positive cells+SD. 
There was no significant difference in the percentages of 7-AAD positive cells for 
unlabeled (10%) or MPIO labeled (16%) MSC (n=3 each). Representative dot plots for 7-
AAD are also shown for one sample where (a) and (b) indicate the percentages of live 
and nonviable cells, respectively. 
3.2.2 Magnetic Resonance Imaging  
3D whole mouse body anatomical images were acquired in the sagittal orientation at 3T 
using a bSSFP pulse sequence in a relatively short time (31min) for high resolution MRI 
at clinical fields. Maintaining a short scan time was important as the secondary effects of 
SCI include diminished thermal regulation, decreased breathing capacity, and deficits in 
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cardiovascular function,47 making the mice more susceptible to complications due to 
anaesthesia and the inherent cold temperature of MRI systems, even when using 
compensating mechanisms. This was a significant consideration as in this longitudinal 
study the mice were scanned up to three times in one week. Figure 3.3 shows a 
representative image of a SCI mouse, which received no cell transplant, two weeks after 
the injury.  The spinal cord has a significant curvature and the entire length of the cord is 
visible.  The epicenter of the SCI is visible as a small, subtle region of altered signal.  In 
SCI mice the contrast at the epicenter of the SCI changes slightly over time becoming 
more hypo-intense.  
 
Figure 3.3: Representative sagittal image of a mouse from Group 5, which received no 
transplant. Two weeks after SCI the lesion site (arrow) is observed as a small, subtle 
region of altered signal. Other organs are labeled for anatomical reference. 
Representative images from a mouse that received a direct transplant of MPIO-labeled 
MSC, show clear areas of signal loss within the cord (Fig. 3.4). This is an example of 
what we refer to as a  ‘successful’ intra-spinal transplant since the images show regions 
of signal loss within the spinal cord on the day of the transplant, and not outside of the 
cord or in surrounding tissues. As the MRI data was acquired in 3D, this allowed for 
manual segmentation in any plane, such as an oblique axial to adjust for the natural 
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curvature of the mouse cord. The bottom panel in Figure 3.4 shows axial images through 
the cord at different levels. This view helps to verify that the areas of signal loss are in 
fact within the cord, close to the central canal (1: blue arrow, Fig. 3.4.b), by the dorsal 
column (2: red arrow, Fig. 3.4.c) and closer to the cerebrospinal fluid (CSF) (3: yellow 
arrow, Fig. 3.4.d). 
 
Figure 3.4: Representative sagittal image (a top) of a mouse that received a successful 
transplant of MPIO-labeled MSC and corresponding cord areas in an axial plane 
(bottom). Clear areas of signal loss were observed within the cord: close to the central 
canal (b, 1: blue arrow), by the white dorsal column (c , 2: red arrow) and closer to the 
CSF (d, 3: yellow arrow). D-dorsal, V-ventral, R-rostral, C-caudal. 
Representative images from SCI mice that received MSC or free MPIO particles 
transplants are shown in Figure 3.5.  In the images of all SCI mice that received 
successfully MPIO-labeled MSC a large, well-defined region of signal loss was observed 
within the cord at the site of the cell transplant (Fig. 3.5a). The MR appearance of the 
transplant site in the cords of mice that received dead, MPIO-labeled MSC (Fig. 3.5b) or 
MPIO particles (Fig. 3.5c) though was similar to that of live MSC. 
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Figure 3.5: Iron-labeled MSC appeared as well-defined regions of signal loss in the 
mouse spinal cord at the site of transplant. Sagittal views of the cord where regions of 
signal loss can be seen at the site of transplantation. The epicenter is indicated by the 
arrowheads. SCI mice that received: (a) live MPIO-labeled MSC, (b) dead MPIO-labeled 
MSC, and (c) MPIO only, at different points post transplantation. The MR appearance of 
dead, iron-labeled MSC was similar to that of live MSC. While the volume of the region 
of signal loss decreased over time for all groups, it was still present in all at the end of the 
study at 6 weeks after transplantation. D-dorsal, V-ventral, R-rostral, C-caudal. 
There was no significant inter-observer variability  (p>0.48) in the measurements of 
regions of signal loss. At day 2 post transplant the average volume of the region of signal 
loss within the cords was 2.5mm3 for live MSC, 1.0mm3 for dead MSC, and 3.5mm3 for 
free MPIO particles.  In all transplanted SCI mice the region of signal loss appeared to 
shrink over time. However, a substantial amount of signal loss persisted at the transplant 
site, in all mice, at the end of the experiment. The rate at which the region of signal loss 
decreased with time varied, although not significantly, for the three groups of mice.  The 
size of the void diminished most quickly in mice that received live MSC and most slowly 
in mice that received MPIO. At six weeks after transplantation the signal void volume in 
mice that received live MSC had decreased to 34±6.6% of the initial volume (an average 
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from n=8, expressed as the mean±SEM). In mice that received dead MSC the void 
volume had decreased to 49±7.5% (from n=4) of the initial volume at six weeks. For the 
group of mice that received MPIO particles the void volume only decreased to 68±22.3% 
(from n=4) the initial value at six weeks.  
Surprisingly, in 4 cases it seemed a successful intra-spinal transplant was not achieved. 
Figure 3.6a shows that, in these mice, no signal loss was observed within the spinal cord 
at the level of the epicenter (arrowhead), the intended site of transplantation. Inspection 
of the 3D image data revealed that signal loss was in the surrounding tissues (arrows).  A 
closer look to a different but nearby MRI slice also shows these areas of signal loss above 
the cord (arrows, Fig. 3.6b). An axial view clearly shows a large area of signal loss above 
the cord with a track that can be followed to the surface (arrows, Fig. 3.6c). 
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Figure 3.6: Representative sagittal image (a) of a mouse where the intended intra-
spinal transplant of MPIO-labeled MSC was not achieved. Areas of signal loss are not 
present within the cord, but can be found in the surrounding tissue. (b) A different slice 
also shows areas of signal loss dorsally of the cord that leave a track to the surface. (c) 
An axial view confirms an area of signal loss on the dorsal left side of the cord, but not 
within the cord. Other organs are labeled for anatomical reference. D-dorsal, V-ventral, 
R-rostral, C-caudal. 
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In 7 cases, where the transplant was deemed successful, additional regions of signal loss 
were observed in unexpected locations, mainly along the dorsal edge of the cord in the 
cervical spinal cord, possibly within the CSF. In Figure 3.7 representative images show 
signal loss in the cervical cord that persisted for 6 weeks, gradually diminishing in size. 
In some cases regions of signal loss were observed in the brain.  
 
Figure 3.7: Areas of signal loss far from the site of transplantation (arrowhead) in a 
mouse that received a direct transplant of MPIO-labeled MSC. The signal loss appears to 
be in the dorsal portion of the first few cervical vertebral segments, aligned and within or 
adjacent to the CSF. The overall pattern of this secondary area of signal loss changed 
slightly week to week, and although smaller in volume it was still present at the end of 
the study.  
In Figure 3.8 signal voids appear in close proximity to the third ventricle in images 
acquired on the same day as the transplant (Fig. 3.8 a&c). The size of these areas of 
signal loss decreased and had subtle changes in the pattern over time but persisted in the 
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same location until the end of the study (Fig. 3.8 b&d). The observation of signal void far 
from the lesion epicenter was not noted in animals that received dead cells or free iron.  
 
Figure 3.8: Sagittal (a&b) and axial (c&d) images of a mouse that received a direct 
transplant of MPIO-labeled MSC. Areas of signal loss were observed on the day of the 
transplant  (a&c) within the brain. Although these areas of signal hypo-intensity 
decreased in size, they were still present at the end of the study at 6 weeks (b) notably 
within the third ventricle (d). Scale bar on b applies to a&b, and on d applies to c&d. D-
dorsal, V-ventral, R-rostral, C-caudal. 
3.2.3 Histology 
MR images of the cord were compared with PPB stained cord sections six weeks after the 
transplant.  In Figure 3.9, representative MRI and PPB staining is compared showing 
good correspondence between the regions of signal loss and blue staining due to iron for 
the animals that received live MPIO-labeled MSC (top row), dead MPIO-labeled MSC 
(middle row), and free MPIO (bottom row). Two different types of PPB staining were 
observed at the injection site, concurrently, and in all groups.  In some areas the PPB 
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staining appeared extracellular (arrowheads, Fig. 3.9c) and frequently formed dense 
clusters (Fig. 3.9i). In other areas the PPB staining appeared intracellular (arrows Fig. 
3.9c) and lighter (Fig. 3.9f).  
 
Figure 3.9: At 6 weeks after the transplant the pattern of signal loss in the MRI images 
of the cord for the animals that received (a) live MPIO-labeled MSC, (d) dead MPIO-
labeled MSC, and (g) free MPIO matched the PPB staining of the cord (b, e , and h). The 
iron was observed in two different patterns, one appeared to be extracellular (c , 
arrowheads) and more concentrated (i), while the other appeared intracellular (c , arrows) 
and usually fainter (f). These two patterns were observed in all groups. 
Figure 3.10 shows an overlay of micrographs of an unstained cord section and after DAPI 
staining of nuclei in the same section.  The DAPI fluorescence image was converted to 
black and white to produce maximum contrast between the black nuclei and the rust 
colored iron.  This microscopy image clearly shows the difference between clusters of 
MPIO particles outside of cells (arrows) and heavily loaded cells (arrowheads). 
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Figure 3.10: An overlay micrograph is shown of unstained cord tissue where MPIO 
particles appear rust colored and DAPI staining of nuclei in the same section. The DAPI 
fluorescence image was converted to black and white to produce maximum contrast. 
Arrows indicate clusters of MPIO particles outside of cells and arrowheads point to 
heavily loaded cells where the nucleus is easily observed. 
Figure 3.11 compares fluorescence images of EGFP with PPB staining near the lesion 
epicenter for a SCI mouse that received live MPIO-labeled MSC. There is good 
agreement between areas containing cells that are EGFP+ and cells that are PPB+.  
Tissue that does not appear to contain any PPB+ cells is not visible in the fluorescence 
image.  Again, some of the areas with blue PPB staining appear denser than others, 
although most of the PPB+ staining appears to be intracellular. While this is an example 
where there is good correspondence between PPB+ and EGFP+, not all PPB+ sections 
were matched to EGFP+ sections.   
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Figure 3.11: In animals that received live iron-labeled MSC, immunostaining showed 
GFP+ areas (a) that could be matched to PPB+ cells (b). Both images taken with a 20x 
objective. 
F4/80 staining revealed macrophages mostly present at the epicenter of the injury (Fig. 
3.12). There were few macrophages detected in the sections from the animals that 
received live, MPIO-labeled MSC (Fig. 3.12a). Sections from SCI mice that received 
dead, MPIO-labeled MSC or free MPIO particles contained many more macrophages 
(Fig. 3.12 b&c). Cells that were both PPB and F4/80 positive were observed only 
occasionally in all mice. For the most part iron positive cells in the cord did not co-
localize with macrophage staining. 
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Figure 3.12: At 6 weeks after transplant, macrophage staining (F4/80) revealed few 
macrophages present at the epicenter of the injury for animals with live, MPIO-labeled 
MSC (a), and more macrophages in animals that received dead, MPIO-labeled MSC (b) 
and MPIO only (c). 
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3.3 Discussion  
Now that cell transplant therapies are being explored for many disorders, interest in the 
use of cellular MRI to track cells in animal models of disease is growing rapidly. There 
are numerous studies that demonstrate that MRI of iron-labeled cells allows for their 
detection after transplantation.2, 48-53 However, cell death and subsequent phagocytosis of 
iron particles by macrophages may render the MRI signal nonspecific for tracking cells 
for long periods of time after transplantation. The results of this paper showed that iron 
oxide labeling and MRI may be useful for the in vivo visualization of the cell transplant 
in the spinal cord but these methods are not reliable for tracking the fate of transplanted 
cells in all tissues and models. 
The main finding of this study is that signal hypo-intensities observed by MRI after the 
transplantation of iron-labeled cells may not reliably represent the original donor cells. 
This was determined by performing a longitudinal imaging study that followed SCI mice 
for six weeks after the direct transplantation of viable iron-labeled MSC, dead iron-
labeled MSC or free iron particles, and where the MRI appearance of the region of signal 
loss at the transplant site was found to be remarkably similar for all three groups.   
In all transplanted SCI mice the volume of signal loss decreased over time. However, a 
substantial amount of signal loss persisted at the transplant site, in all mice, at the end of 
the experiment. The reduction in volume of signal loss was not surprising since many 
stem cells are expected to die from the transplant itself54 and in the hostile environment 
of SCI.55 The direct transplantation of stem cells into target tissues is known to result in a 
large percentage of the donor cells dying. Coyne et al. transplanted GFP+ MSC into the 
rat striatum and found that the surgery itself elicited an immediate inflammatory 
response, MSC grafts were massively infiltrated by microglia/macrophages and by 14 
days, the GFP immunoreactivity was absent, indicating complete donor rejection.56 In a 
similar model Moloney et al. also reported a considerable reduction in the size of the 
graft volume by day 7, albeit MSC were still detectable by day 42 after transplantation.57 
Both reports are in agreement with a study by Xu et al. that reported that there is a 
significant decrease of directly transplanted MSC within the first few weeks in a SCI 
mouse model with only ~3% cells surviving past 3 weeks and less than 1% by 6 weeks.55 
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The decline in the size of the original signal void volume was greatest in SCI mice that 
received live MPIO-labeled cells. There were also very few macrophages in the spinal 
cord sections from mice transplanted with viable MSC. This is expected since 
macrophage infiltration due to SCI peaks at 5-7 days and then slowly decreases over the 
next 2-5 weeks.58 In addition, the administration of MSC in mouse SCI has been shown 
to have a beneficial effect attributed to a reduction in the number of monocyte-derived 
macrophages at the injury site.55 Although the cell number is expected to decline with 
cell death and the signal void volume decreased with time, the void volume is probably 
an overestimation of the live MPIO-labeled MSC since some bystander cell uptake of 
iron is likely. 39 
The fact that the size of the void diminished more slowly in the mice that received dead 
MPIO-labeled cells, and even more so in mice that received free MPIO, was interesting. 
PPB staining showed areas of dense extracellular iron present in the injured cord tissue at 
6 weeks post transplant. The free iron particles purposefully transplanted into the injured 
cord were also found lodged in the damaged cord tissue at 6 weeks post injection.  These 
observations are consistent with those of Berman et al. where iron from cells transplanted 
directly into the mouse brain was retained in the extracellular space in brain tissue for 
long periods of time making it difficult to distinguish between viable and dying cells.59, 60 
There were many more macrophages present in the cords from mice injected with dead 
MSC or free MPIO particles, compared to the cords of mice that received live MSC. The 
presence of free MPIO particles and dead MSC may trigger an additional inflammatory 
response increasing the number of macrophages present at the site of transplant. 
Macrophages may engulf dead cells and their debris, becoming iron-labeled 
secondarily.61 In addition, the possibility exists for the transplanted cell population to 
contain cells with iron particles attached to their surface, or to contain free iron particles 
in the solution, and in both of these situations there is the potential for the iron particles to 
be released into the target tissue and taken up by bystander cells. Therefore, although 
MRI of iron-labeled cells is very useful for locating transplanted cells and for evaluating 
the delivery of transplanted cells to the target tissue in the early phase, the potential for 
transfer of the iron label to other cell types in the longer-term is a significant limitation. 
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Our results are consistent with a study by Jackson et al. where live and dead iron-labeled 
MSC were transplanted directly into the injured striatum in a rat model of Parkinson’s 
disease. The region of signal void due to live iron-labeled MSC was tracked in vivo for 
28 days.  The signal loss due to dead iron-labeled MSC appeared similar but became 
fainter after 21 days.62 Pawelszyk et al. have quantified the frequency of the transfer of 
intracellular labels to host macrophages that phagocytosed the label or labeled cells.63, 64 
They concluded that only 5-15% of the iron label was taken up by the host macrophages. 
Dunning et al. transplanted MPIO-labeled Schwann cells (SC) directly into toxin-induced 
demyelinating lesions in the rat spinal cord and imaged the rat spinal cord in vivo at 5 
days post transplant and ex vivo at 4 weeks post transplant. To establish the contribution 
of labeled SC to the observed signal void, the number of SC containing MPIO were 
counted. They calculated that >50% of the SC in the lesion retained at least one 
microsphere. MPIO particles were also observed within macrophages. The ratio of 
labeled MPIO+ SC to MPIO+ macrophages was 2:1.65  The observation of transfer of the 
iron label from donor cells to macrophages has also recently been reported in three papers 
where stem cells were transplanted directly into the rat heart.39, 66, 67  
Ours is the first study to use in vivo MRI to monitor the fate of stem cells after their 
direct transplantation into the injured spinal cord in mice. Sykova et al. showed that iron-
labeled MSC administered i.v. in SCI rats can be detected as regions of signal loss in ex 
vivo images of the cord at 4 weeks after the cell injection.16, 68  They also showed that 
iron positive cells in the cord did not co-localize with macrophage staining, suggesting 
that iron labeled MSC persist and can be tracked with MRI. Our findings, after direct 
transplantation of MSC in SCI mice, are comparable. 
The homing of iron-labeled stem cells, after their systemic administration, has also been 
evaluated by MRI.5, 69, 70 Song et al. used MRI to detect iron-labeled human NSC that had 
been administered i.v. in a rat model of focal cerebral ischemia.5 The maximal signal 
hypo-intensity was observed at 28 days after i.v. injection.  Histology showed PPB+ 
cells, which were identified as grafted human NSC, and not phagocytic macrophages, 
because they did not express the activated microglial/macrophage markers OX6 and 
BrdU. MRI has also been used to track a variety of other cell types in disease models. For 
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example, iron-labeled pancreatic islets have been transplanted into the mouse liver by 
intraportal infusion in a model of diabetes with the goal of restoring insulin.  Regions of 
signal loss were detected in the liver immediately after the islet transplantation.  The 
regions of signal loss due to isografts persisted in the liver much longer than the signal 
loss due to allografts and xenografts, which disappeared from the images with time as the 
islets were rejected.71 The adoptive transfer of iron-labeled DC in mice has been 
successfully monitored using MRI. Here the subcutaneous injection of DC into the 
footpad resulted in the migration of DC to the draining popliteal lymph node, which was 
detected as signal loss in the node two days after the injection.  This signal loss was no 
longer apparent at 7 days post injection, nor were DC detected by histology, indicating 
that the DC, which have a lifetime of 4-7 days, had been cleared.72 Collectively, the 
results of many recent studies indicate that the MRI appearance of transplanted cells must 
be interpreted with caution and that the identity of donor cells must be carefully validated 
by histology. 
It was interesting to find areas of hypo-intensity in the brain and dorsal cervical areas of 
the cord in animals that received live MPIO-labeled MSC. These signal voids appeared to 
be in close proximity to, or within, the CSF.  The enlargement of CSF containing 
structures after traumatic SCI has been reported in rabbits and rodents.73, 74 Changes in 
CSF flow direction and pressure have been proposed as mechanisms that promote the 
development of cysts.75 The presence of cysts in the mouse cord (as shown in Chapter 2) 
may lead to abnormal CSF flow which might explain the movement of iron-labeled cells 
rostral to the injection site as early as the day of transplant, and this could explain these 
areas of signal loss.  These areas of signal loss were not observed in animals that received 
dead cells or free MPIO.  
While MRI long-term cell tracking needs to be approached with caution and thoroughly 
validated through histology, MRI does allow us to verify the delivery of the cells to the 
intended target in vivo. In experimental studies of stem cell transplantation this is 
important because the stem cell survival and homing is typically assessed by histological 
analysis at endpoint.17, 55 MRI can provide knowledge that the cells were delivered to the 
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intended target in the first place so that only those successful transplants are included in 
the final histological evaluation.  
Since there is currently no consensus regarding the best route of delivery of cells for stem 
cell therapy MRI may be useful for evaluating the likelihood of successful cell delivery 
with the various methods being considered for SCI in the clinic including intra-arterial36 
and intravenous34, 37 infusions, lumbar puncture,76 and direct transplantation.35 De Vries 
et al.,77 labeled dendritic cells (DC) with SPIO to evaluate the success of injections 
directly into the lymph nodes of melanoma patients. While the injections were performed 
under ultrasound guidance by an experienced radiologist, they reported that ~50% were 
failed injections. They also described, that cell migration to nearby nodes was only 
observed in the patients that had a successful injection and that this should be considered 
as a potential explanation for the lack of response to DC vaccinations in a number of 
patients in ongoing clinical trials.  
 
3.4 Conclusion 
MRI of iron-labeled cells is very useful for locating transplanted cells and for evaluating 
the delivery of transplanted cells to the target tissue in the early phase; however, signal 
hypo-intensities observed by MRI after the transplantation of iron-labeled cells may not 
reliably represent the original donor cells because of the potential for transfer of the iron 
label to other cell types. This was determined by performing a longitudinal imaging study 
that followed SCI mice for six weeks after the direct transplantation of viable MPIO-
labeled MSC, dead MPIO-labeled MSC or free MPIO particles, and where the MRI 
appearance of the region of signal loss at the transplant site was found to be remarkably 
similar for all three groups. 
The methods of transplantation, host tissue, cell type, cell lifespan, and the extent of 
inflammation in the model system, no doubt play important roles in the cell survival and 
clearance.  The direct transplantation models, as described here for the injured spinal 
cord, and as frequently reported for the injured myocardium, may represent the worst-
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case scenario for cell tracking with MRI.  In our SCI model the passage of cells through 
the needle used for the transplantation did not cause a significant amount of cell death, 
however the site of the injection is a hostile environment due to ongoing inflammation 
and the blood flow in the injury is compromised due to the traumatic insult. 
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Chapter 4  
4 In Vivo Magnetic Resonance Imaging Of Acute 
Inflammation After Spinal Cord Injury In The Rat: A 
Preliminary Study 
Impaired sensory and motor function in people who have a spinal cord injury (SCI) is the 
result of not only the initial traumatic event, but also the inflammatory response to SCI, 
which further damages the neural pathways, exacerbating motor and sensory deficits. The 
inflammatory response involves the activation of microglia and the infiltration of 
neutrophils, macrophages, and T-lymphocytes following the initial trauma to the spinal 
cord.1-3 The macrophages involved in the inflammatory response to SCI have been long 
considered to have a dual, ‘double-edged’ role in SCI.4 A recent report shows that this 
may be in fact due to two separate subsets of macrophages present at the lesion site, with 
alternatively activated macrophages (M2) having a positive role in SCI (by contributing 
to the debridement and healing process) and classically activated macrophages (M1) 
having a negative role in SCI (by exacerbating the injury through the release of toxic by-
products and by amplifying the inflammatory responses).5 Kigerl et al. have shown that 
during the first 1-3 days after SCI the presence of M1 and M2 is equivalent, but by the 
end of the first week the M2 have mostly disappeared and the M1 dominate.5 A better 
understanding of the macrophage response is important for planning anti-inflammatory 
treatments and cell therapy.6 Imaging macrophage infiltration in vivo may help to 
elucidate their role in SCI.  
MRI has been used to detect and monitor macrophages in many different preclinical 
disease models.  This is achieved by the intravenous (i.v.) administration of iron oxide 
nanoparticles, followed by imaging, typically 24 hours later.  MRI has been used to 
image inflammation in experimental autoimmune encephalomyelitis (EAE)7-10, ischemic 
stroke,11 atherosclerosis,12, 13 peripheral nervous system injury,14, 15 arthritis,16 SCI,17 and 
rejection in a variety of transplantation models.18-23 This approach has also been used in 
patients for monitoring macrophage infiltration and responses to treatment, in multiple 
sclerosis (MS),24 atherosclerosis,25, 26 lymph node imaging,27 and liver imaging.28, 29 
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All three of the general classes of iron oxide nanoparticles have been used for 
macrophage imaging, including the ultra-small superparamagnetic iron oxide 
nanoparticles (USPIO),30, 31 the standard superparamagnetic iron oxide nanoparticles 
(SPIO),10, 14, 17 and micron-size oxide iron particles (MPIO).32, 33 USPIO have been used 
most frequently because their small size allows them to circulate longer, avoiding quick 
uptake by the reticuloendotheial system.  MPIO are only used in preclinical studies since 
they are inert. 
In SCI, macrophage imaging has yet to be performed in vivo.  A previous study from our 
lab evaluated the use of iron nanoparticles for the labeling and detection of macrophages 
in the injured rat cord using ex vivo MRI at 1.5T.  This study demonstrated that clusters 
of iron-labeled cells associated with the inflammatory response in SCI could be detected 
in bSSFP images of the rat cord.17 The purpose of this study was to implement techniques 
for macrophage imaging in vivo in a rat model of traumatic SCI.  
 
4.1 Methods 
4.1.1 Animal Model 
All protocols for these experiments were approved by the University of Western Ontario 
Animal Care Committee in accordance with the policies established by the Canadian 
Council on Animal Care.  
A moderate clip compression SCI was induced in 18 female Wistar rats at the level of the 
4th thoracic (T4) vertebrae as it has been previously described.34 Rats were premedicated 
with atropine sulfate (0.05 mg/kg s.c.; MTC Pharmaceuticals, Cambridge, ON, Canada) 
and placed on a heating pad to maintain body temperature. Surgical anesthesia was 
achieved using isoflurane USP (5% to induce and 2% to maintain; Abbott Laboratories, 
Saint-Laurent, QC, Canada) in oxygen at a rate of 2 l/min, delivered through a nose cone. 
With the assistance of a surgical microscope, a laminectomy was performed to expose the 
T4 segment of the spinal cord and a modified aneurysm clip was used to compress the 
cord extradurally for 60 seconds, with a force of 35g. The muscles and the skin were 
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closed with 4-0 Vicryl and the animals were allowed to recover under a heating lamp. All 
animals were treated with buprenorphine (0.1 mg/kg s.c.; Temgesic, Schering-Plough, 
Hertfordshire, UK) as needed and 5 mg/kg of Baytril (Bayer, Toronto, ON, Canada) and 
5ml  of 0.9% saline twice daily for three days. Bladders were voided twice daily by 
manual compression.  
4.1.2 Magnetic Resonance Imaging 
Rats were imaged using a 3 Tesla (3T) whole-body MR scanner (MR Signa® Excite™, 
GE Healthcare, Milwaukee, WI, USA ) using a custom-built gradient coil (inner 
diameter=17.5cm, maximum gradient strength=500 mT/m, and peak slew rate=3000 
T/m/sec). Rats were anesthetized with isoflurane (2%) and placed on a custom-built 
Plexiglas tray to permit careful and reproducible positioning to allow sagittal imaging of 
the cord. The tray was positioned within a custom-built radiofrequency (RF) transmit-
only, receive-only (TORO) system (Fig. 4.1). The TORO system consisted of a 4-channel 
phased array receiving RF coil (diameter=7.5cm, length=6.25cm, Fig. 4.1a), nested in a 
birdcage RF coil (diameter=12cm, length=16.5cm, Fig. 4.1b) that transmits the RF 
excitation pulse. Surface coils as receiving coils offer a high signal to noise ration (SNR) 
but have limited surface field of view (FOV) and depth. Arranging a number of surface 
coils in a phased array, 4 in this case, allows for a more homogeneous FOV over a 
volume while taking advantage of the SNR of each individual surface coil. The drawback 
is that surface coils fail to produce a uniform field in the transmit mode, which can be 
circumvented by having a separate transmitting coil. While a solenoid coil like the one 
used in Chapters 2 and 3 provides the most homogeneous excitation, the solenoid coil 
must be placed perpendicular to the main field within the insert coil, which is not possible 
with a rat due to size constraints. The next best option is a birdcage transmit coil that will 
provide homogenous excitation with the phased array exploiting the SNR from a 
receiving surface coil. 
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Figure 4.1: Radiofrequency (RF) transmit-only, receive-only (TORO) system. The 
receive-only RF coil is a 4-channel phased array, 6.25cm in length (blue line) and 7.5cm 
in diameter (a). The transmit-only birdcage RF coil is 16.5cm in length (blue line) and 
12cm in diameter (b). The tray holding the rat (blue arrow) is nested at the center of the 
system, surrounded by the receiving coil, which is in turn nested in the center of the 
transmitting coil (c). 
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The body and tail of the rats were wrapped using surgical bench diapers to maintain body 
temperature. Rats were scanned at a 200µm isotropic resolution using a 3D balanced 
steady state free precession (bSSFP) pulse sequence (3D-FIESTA; GE Medical Systems, 
Milwaukee, WI, USA ) with the following parameters: FOV=6cm x 3.6cm, 280 locs/slab, 
BW=±27.78kHz, TE/TR= 3.8/7.6ms 4 NEX, 4 RF phase cycles, and α=40º. Following 
each and every scan, rats recovered under a heating lamp.  
A baseline scan was acquired 3 days after SCI and then USPIO (Molday ION™, 
BioPAL, Worcester, MA, USA ) was injected i.v. and the animals were imaged again 24 
hours later with the same parameters. Three doses were compared: 5mg/kg (n=3), 
15mg/kg (n=7), and 30mg/kg (n=3); n=5 received no iron.  
4.1.3 Image Analysis 
To assess the image quality after the three different doses of USPIO the SNR was 
calculated.  An elliptical ROI was placed within the cord image, at least 4 vertebral 
segments rostral to the epicenter, to measure the average signal intensity and this was 
divided by the standard deviation of the background (‘noise’), which was measured from 
a rectangular ROI selected within the same image: 
𝑆𝑁𝑅 = 𝐶𝑜𝑟𝑑 (𝑚𝑒𝑎𝑛)𝑁𝑜𝑖𝑠𝑒 (𝑆𝐷)  
A SNR value was determined for each cord by averaging the calculated SNR from 10 
images for each animal. SNR was compared between groups with a one-way ANOVA. 
Images of injured cords were assessed for changes in signal intensity at the lesion 
epicenter in images acquired before and after iron oxide administration. Two elliptical 
ROIs were drawn in all cord images. One ROI was drawn in the cord at least 5 vertebral 
segments rostral to the epicenter, as a measure of ‘background’ cord signal intensity. The 
second ROI was drawn within regions of abnormal signal hypo-intensity at the lesion 
epicenter. These ROIs were drawn in approximately the same location for images 
acquired pre and post iron (equivalent slices matched by visual inspection). The contrast 
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between these two regions was measured as the fractional signal loss (FSL). FSL was 
calculated as: 
𝐹𝑆𝐿(%) = ∆𝑆𝑆 = 𝑐𝑜𝑟𝑑 𝑚𝑒𝑎𝑛 − 𝑐𝑜𝑟𝑑 min𝑐𝑜𝑟𝑑 𝑚𝑒𝑎𝑛 x100 
At least 5 images slices for each animal from each imaging session were used to calculate 
an average FSL. Colored maps of the MR signal intensity were made for enhanced 
visualization of the regions of signal loss after iron injection. This was done using a 
UCLA color lookup table (CLUT).  All segmentation and coloring was made using the 
open-source imaging software OsiriX.35  
4.1.4 Histology 
After the final imaging session the rats were induced with deep anesthesia and 
transcardially perfused. The spinal cords were removed and placed in phosphate buffer 
up a sucrose gradient (10%, 20%, 30%) at 4°C. Cord tissue was sagittally sectioned on a 
cryostat set at 20µm. The sections, which were ~15mm in length with the lesion epicenter 
in the middle of the section, were serially collected on gelatin-coated glass slides, 
alternating between two slides. For each animal half the slides were stained with Perls’ 
Prussian Blue (PPB), for visualization of the iron particles, and nuclear fast red for 
visualization of the cord and lesion morphology. Stained sections were visualized using 
optical microscopy with a Zeiss AXIO Imager (Carl Zeiss Canada Ltd.; Toronto, ON, 
Canada).  
 
4.2 Results 
Figure 4.2 shows representative images of the injured rat cord on day 3 post SCI, before 
USPIO (a), and on day 4 after SCI, 24hrs after USPIO at a dose of 30mg/kg of Molday 
IONTM (b).  The injured cord appears with regions of heterogeneous signal at the lesion 
epicenter by day 3 post SCI.  Regions of signal hyper-intensity due to edema can be seen 
on both sides of the lesion epicenter (arrows) (Fig. 4.2a). Some small areas of hypo-
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intensity are also often observed at this time point. After the administration of USPIO the 
contrast in the lesion epicenter is changed (Fig. 4.2b) with more obvious signal loss.  
Figure 4.2: Lesion epicenter in an animal on day 3 after SCI (a) and on day 4, 24hrs 
after an injection of 30mg/kg USPIO (b). White arrows point to the same region in both 
images, which appears with more contrast (regions of low signal) after iron injection. 
Figure 4.3 shows representative bSSFP images of three different rat cords after the 
administration of three different doses of USPIO. The 5mg/kg dose subtly enhanced 
some areas of the lesion epicenter (Fig. 4.3a), with the 15mg/kg dose there appeared to be 
additional regions of signal void in the cord in all animals, compared to the smaller dose 
(Fig. 4.3b), and the 30mg/kg dose produced a more obvious enhancement, but with a 
substantial drop in SNR (Fig. 4.3c). The SNR of the cord, rostral to the lesion site, for 
each dose is shown in Table 4.1. While the detection of signal void appeared to increase 
with dose, the SNR of the cord tissue away from the injury decreased as the dose 
increased.  The differences in SNR were significantly different between the groups, 
which received different iron doses. 
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 Figure 4.3: All three doses of USPIO enhanced the area of the injury, by creating 
areas of signal loss (blue arrows), although there were subtle differences in enhancement 
at the different doses 5mg/kg (a), 15mg/kg (b), and 30mg/kg (c) and bigger differences 
in SNR (Table 4-4).  
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Table 4-1: Spinal cord SNR at the different doses, from n=3 for each dose. Average 
SNR is calculated from 10 images for each animal.  
Dose SNR Fig 4.5 
5mg/kg 22.7 a 
15mg/kg 24.1 b 
30mg/kg 17.3 c 
Differences in the amount of iron accumulating at the lesion site could also been 
visualized in the cord tissue at gross inspection (Figure 4.4).  
 
Figure 4.4: In the tissue at the lesion epicenter 24hrs after USPIO injection and on day 
4 after SCI there were rust-like areas that seemed to deepen in color as the dose 
increased.  
The FSL was measured for two SCI rats.  The FSL increased between day 3 (prescan) 
and day 4 (24hrs after USPIO injection) indicating that these areas had an increased 
108 
 
contrast due to signal loss. Table 4.2 and Figure 4.5 show the FSL values for two SCI 
rats.  
Table 4-2: FSL for two animals before and after USPIO injection from an average of 5 
images for each scan. FSL: average fractional signal loss, SD: standard deviation 
ID Day 3 (prescan) Day 4 (24hrs post USPIO) 
 FSL SD FSL SD 
R5 11.1% 6.2% 42.7% 7.1% 
R6 30.4% 4.6% 55.4% 5.4% 
 
 Figure 4.5:  FSL in the cord in two SCI rats before and after USPIO injection from the 
data presented in Table 4.1.  
A color lookup table (CLUT) was used to create pseudo-colored MR images to enhance 
the visualization of areas that became hypo-intense after USPIO injection (Figure 4.6). In 
the prescan images (left), the cord signal intensity is more uniform. In the post USPIO 
images (right) the arrows point to regions within the cord where signal loss appeared.  It 
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is easier to see the changes from light blue to a dark blue, as signal intensity drops in the 
presence of iron, in the cord in the pseudo-colored images compared to the gray scale, 
where the hue difference appears subtler.  
Figure 4.6: Adjacent image slices from a representative rat spinal cord on day 3 after 
SCI (prescan, left) and on day 4 after SCI (24hrs after USPIO injection at a dose of 
15mg/kg, right).  
Figure 4.7 shows an MRI image (a) of a SCI-only animal on day 4 after SCI with a 
corresponding histological section at 5x magnification (b) stained with PPB and nuclear 
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fast red.  These images are centered on the lesion epicenter covering four vertebral 
segments. In the MRI image, areas of signal hypo-intensity (white arrow) can be seen. In 
the histological section these areas are PPB+ (black arrow). Zooming in on that region at 
10x (Fig. 4.7c), 40x(Fig. 4.7d), and 100x (Fig. 4.7e) gives a closer view of that PPB+ 
region. The iron appears clustered in many areas and for the most part does not appear to 
be intracellular.  
 
Figure 4.7: In SCI-only animals, at day 4 after SCI, there are areas of signal loss 
present in the MRI images (a), which match the PPB+ areas in histology (b). Zooming in 
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on the area denoted by the square on b at 10x (c), 40x (d), and 100x (e) gives a closer 
look to these regions PPB+ due to hemorrhage  
In Figure 4.8, a representative bSSFP image is shown for a USPIO injected rat (a) on day 
4 after SCI alongside the corresponding histological section at 5x magnification (b) 
stained with PPB and nuclear fast red. In the MR image, the areas of signal hypo-
intensity can be easily seen (white arrow) at the lesion site. In the histological section 
though, at this lower magnification (5x) these areas are PPB+ (black arrow) would be 
difficult to distinguish from a SCI-only animal as shown in the previous figure. This is 
not surprising as there will also be hemorrhage besides the USPIO. At higher 
magnification however, the appearance of the PPB staining was different from the SCI 
only cord tissue. Zooming in on that region at 10x (Fig. 4.8c), 40x(Fig. 4.8d), and 100x 
(Fig. 4.8e) most of the PPB+ areas look punctuate and intracellular (Fig. 4.8e, purple 
arrow), an appearance not observed without USPIO injection. These are likely USPIO 
particles phagocytosed by macrophages as previously shown in an ex vivo imaging study 
of rat SCI.17 
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Figure 4.8: In an animal that received a 30mg/kg USPIO injection the areas of signal 
loss present in the MRI images (a), also match the PPB+ areas in histology (b) at day 4 
after SCI. At higher magnification, on the area denoted by the square on b at 10x (c), 40x 
(d), and particularly 100x (e), some of these PPB+ areas show an intracellular punctuate 
pattern (purple arrows) 24hrs after USPIO injection.  
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4.3 Discussion 
The work performed in this chapter represents a preliminary investigation of the use of 
iron oxide nanoparticles and MRI for the detection of inflammation in vivo in rat SCI. A 
previous study in our lab had investigated the potential for macrophage imaging in rat 
SCI by imaging ex vivo injured rat cords with bSSFP at 1.5T.  Our goal here was to 
implement the techniques required for in vivo imaging of macrophages in the rat at 3T 
and to validate the imaging results with histology.  Our strategy was to image with bSSFP 
utilizing a TORO RF coil system and a high performance insertable gradient coil on a 3T 
whole body scanner.  
We used a USPIO agent to label cells in situ.  The USPIO was administered at day 3 post 
SCI and imaging was performed 24 hours later.  This timeframe was selected because 
histological studies have demonstrated that the number of macrophages in the injured rat 
cord tissue begins to increase at 2 days post SCI and peaks between 5-7 days post SCI 
with a robust macrophage presence by day 3 after SCI, which includes blood derived 
macrophages.2, 17, 36-38 Furthermore,  this was confirmed by a recent study that looked at 
both blood and cord inflammatory cascade using flow cytometry over a period of 12hrs to 
96hrs after SCI.39 In this study Stirling and Yong showed that 24hrs after SCI there was 
an increase in blood monocytes that was sustained for at least 4 days after SCI. This 
timing would therefore target macrophages that were infiltrating the cord.  Although all 
three types of commercially available iron oxide agents have now been used for 
macrophage imaging we chose to use USPIO because of its relatively long circulation 
time in vivo (several hours).  In addition, in a pilot experiment where we tested both 
USPIO and MPIO we observed more signal loss in the injured cord after USPIO and we 
had some mortality after i.v. MPIO at the largest dose (30 mg/kg).  
We compared three doses of USPIO: 5, 15 and 30 mg/kg body weight given i.v.  
Although various USPIO has been used in rodents for many macrophage imaging studies 
the use of this particular, and newly available, USPIO (Molday ION™ from BioPAL) has 
not been published and so an optimal dose was not clear.  Our intermediate dose was 
close to the dose recommended for USPIO by Dousset et al.30 and we tested doses above 
and below this. We observed an increase in the amount of signal loss within the lesion 
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epicenter in the cord in images acquired after all three doses of USPIO. Although 
shimming was increasingly difficult as the USPIO dose was increased, due to the high 
iron content within the rat body, the highest dose of USPIO is likely the optimal since the 
ability to detect macrophage infiltration will improve with greater iron content at the 
lesion site.   
Quantification of the signal loss due to iron remains a challenge in cellular MRI. In this 
study we tested the FSL as a method to quantify the contrast of regions of signal void that 
appeared in the lesion after i.v. USPIO.  Essentially this measures how black the void is.  
In previous studies in our lab we showed that for single iron-labeled cells there is a linear 
relationship between the FSL and the iron per voxel within a particular range of 
loadings.40   We found a statistically significant increase in the spinal cord lesion FSL in 
cord images obtained after USPIO compared to prescans which suggests that there is an 
increase in the intracellular iron content. Other models use a contralateral side for 
comparison,41 but in the case of the spinal cord that was not possible, which makes it 
more complicated to set thresholds or histograms. We did attempt setting a threshold 
value for signal intensity so that all pixels below a certain value could be attributed to the 
USPIO; however, because there was a difference in signal range from animal to animal 
and between different days and doses, that was not possible; a single threshold would not 
work across all cases. Measuring a volume of hypo-intense areas was also attempted by 
creating a pixel histogram; though, without automatic registration and segmentation this 
was not feasible to perform in all animals. Doing manual segmentation on the original 
acquisition presented specific challenges in defining a range of spinal cord to cover as the 
animals were not exactly aligned the same way on both days and as we got close to the 
edges of the cord there were areas of signal loss due to the vertebrae that complicated the 
segmentation. While it would be possible to digitally re-slice the cord into a different 
plane such as axial, this presented the complication of analyzing over 500 
images/animal/day. Not only was that not practical, but because the signal dropped 
towards the edges of the coil some slices would need to be excluded, which presented 
new challenges as the animals were not in the exact position on both days and would 
need to be registered one day to the other to verify identical coverage on both days.  
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In cellular MRI studies of neuroinflammation, signal loss has been attributed to the 
accumulation of infiltrating iron-labeled macrophages. This is because in situ labeling is 
based on the assumption that phagocytic cells in the blood during an immune response 
can be targeted with an i.v. injection of (U)SPIO, and these cells will migrate to the site 
of inflammation carrying the magnetic label with them. However, it is difficult to prove 
that the signal loss in the cord lesion after i.v. USPIO is due to the presence of iron-
labeled macrophages.  We performed histology and stained the cord tissue with PPB to 
detect iron.  Correlating histological slices with images slices is always challenging 
because not every contiguous tissue slice is sectioned and stained, and there is a large 
discrepancy between the slice thicknesses (MRI=200 µm, histology =20 µm).  In addition 
tissues are distorted due to processing and perfect alignment is not possible.  Our PPB 
stained sections showed that PPB staining was observed in the cords from SCI rats that 
did and did not receive USPIO, which was not surprising as in traumatic SCI a significant 
amount of hemorrhage occurs. PPB staining is the classic method for demonstrating iron 
in tissues and is commonly used to detect iron associated with hemorrhage. The PPB 
staining looked different though in SCI cords from rats that had received i.v. USPIO 
compared to those that had not.  For the animals that received USPIO, most of the iron 
appeared to be intracellular with little PPB staining in areas outside of cells.  In rat cords 
from SCI-only animals the PPB appeared in large dense clumps and appeared to have 
spilled out of the parenchyma. This data suggests that after i.v. USPIO is administered in 
SCI rats iron can be detected intracellularly in the cord lesion site. We cannot conclude 
that we have detected macrophages however, since we have not performed a specific 
stain. 
To identify the cells that are being labeled with i.v. USPIO many studies have used 
macrophage stains along with PPB.7, 22, 42 Several studies have compared MRI findings 
with immunohistochemical analyses with ED1, a marker for activated macrophages in 
rats, and showed that regions of signal loss in MR images correspond to cells in 
inflammatory lesions that are ED1-positive. This may be useful for SCI as well, however, 
it would not be specific since all phagocytosing macrophages (hematogenous 
macrophages and microglia) in the rat are recognized by the monoclonal antibody (mAb) 
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ED1. Furthermore, all of the macrophage subsets have been implicated in the 
pathogenesis of SCI, are naturally phagocytic, and have the potential to internalize iron 
nanoparticles.   
While our intent was to label and image hematogenous macrophages, there are other cell 
types that could be labeled this way.  For example, microglia, the resident macrophages 
in the CNS, are known to become activated in SCI and are also highly phagocytic.  In 
SCI the integrity of the blood-spinal cord barrier is severely compromised, and while it is 
possible that nonspecific USPIO uptake could occur and is conceivable that cells already 
present in the lesion at the time of USPIO administration could be labeled passively, 
previous studies in MS models and patients have shown that this is unlikely.43-45 These 
studies have shown no USPIO passively diffusing through a broken blood brain barrier 
(BBB)43, 44 that would result in resident microglia becoming labeled and conversely have 
shown USPIO enhancement in lesions with an intact BBB that could only be attributed to 
infiltrating macrophages.45  
Oweida et al. provided the first direct evidence that SPIO-labeled hematogenous 
macrophages are labeled in situ after i.v. administration of Feridex, and that these cells 
contribute to the regions of signal loss observed in MR images in a mouse model of MS. 
This was achieved using a novel mouse model in which hematogenous macrophages are 
GFP-positive and microglia are GFP-negative. They showed excellent correspondence 
between areas in the brain that are PPB-positive and GFP-positive and regions of signal 
loss observed in bSSFP brain images.46 
Validation of signal loss is also challenging because there are other sources of signal 
hypo-intensity in MR images.  Other things appear with low signal intensity in our 
bSSFP images including bone, air (e.g. lungs, trachea, occasional air pockets developed 
during surgery) and artifacts (banding in bSSFP) due to inhomogeneities.  In this model 
in particular the lesion is an issue since there will be hemorrhage of various stages, 
scarring and gliosis, all of which contribute to a heterogeneous lesion signal. The amount 
of each of these pathologies will also be variable due to inherent biological differences 
between animals that will have different responses to the injury.  Recent strategies to 
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address this challenge include the use of positive contrast agents for cell labeling47-49 and 
pulse sequences that generate positive contrast from iron oxide agents.50, 51 
In conclusion, in this experiment the tools required for in vivo imaging of inflammation 
in SCI were implemented on a specialized imaging system at 3T. This is the first study 
using cellular MRI to image cells within the lesion in vivo in a rat SCI model. 
Furthermore, it was also the first demonstration of the use of bSSFP at 3T for rat body 
imaging. Despite the many challenges for validating macrophage imaging with MRI our 
results are promising and future work will focus on further development of these cellular 
imaging techniques.  
The immune response that accompanies SCI contributes to both injury and reparative 
processes.  The application of in vivo cellular MRI to detect cells involved in these 
immune responses and to evaluate the numbers of cells and spatial patterns of cells and 
changes in these markers in response to anti-inflammatory treatments would be an 
extremely valuable tool for studying SCI and many other preclinical models of 
inflammation and rejection.  
 
4.4 References 
1.   Fleming JC, Norenberg MD, Ramsay DA, et al. (2006) The cellular 
inflammatory response in human spinal cords after injury. Brain 129(Pt 12):3249-
3269. 
2.   Sroga JM, Jones TB, Kigerl KA, McGaughy VM, & Popovich PG (2003) Rats 
and mice exhibit distinct inflammatory reactions after spinal cord injury. J Comp 
Neurol 462(2):223-240. 
3.   Kigerl KA, McGaughy VM, & Popovich PG (2006) Comparative analysis of 
lesion development and intraspinal inflammation in four strains of mice following 
spinal contusion injury. The Journal of comparative neurology 494(4):578-594. 
4.   Donnelly DJ & Popovich PG (2008) Inflammation and its role in 
neuroprotection, axonal regeneration and functional recovery after spinal cord 
injury. Experimental Neurology 209(2):378-388. 
5.   Kigerl KA, Gensel JC, Ankeny DP, et al. (2009) Identification of two distinct 
macrophage subsets with divergent effects causing either neurotoxicity or 
118 
 
regeneration in the injured mouse spinal cord. The Journal of neuroscience : the 
official journal of the Society for Neuroscience 29(43):13435-13444. 
6.   Gensel JC, Donnelly DJ, & Popovich PG (2011) Spinal cord injury therapies in 
humans: an overview of current clinical trials and their potential effects on intrinsic 
CNS macrophages. Expert Opin Ther Targets 15(4):505-518. 
7.   Wuerfel J, Tysiak E, Prozorovski T, et al. (2007) Mouse model mimics multiple 
sclerosis in the clinico-radiological paradox. Eur J Neurosci 26(1):190-198. 
8.   Oweida AJ, Dunn EA, Karlik SJ, Dekaban GA, & Foster PJ (2007) Iron-oxide 
labeling of hematogenous macrophages in a model of experimental autoimmune 
encephalomyelitis and the contribution to signal loss in fast imaging employing 
steady state acquisition (FIESTA) images. J Magn Reson Imaging 26(1):144-151. 
9.   Dousset V, Ballarino L, Delalande C, et al. (1999) Comparison of ultrasmall 
particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, 
and gadolinium-enhanced T1-weighted MR images in rats with experimental 
autoimmune encephalomyelitis. AJNR. American journal of neuroradiology 
20(2):223-227. 
10.   Oweida AJ, Dunn EA, & Foster PJ (2004) Cellular imaging at 1.5 T: detecting 
cells in neuroinflammation using active labeling with superparamagnetic iron 
oxide. Mol Imaging 3(2):85-95. 
11.   Kim J, Kim DI, Lee SK, et al. (2008) Imaging of the inflammatory response in 
reperfusion injury after transient cerebral ischemia in rats: correlation of 
superparamagnetic iron oxide-enhanced magnetic resonance imaging with 
histopathology. Acta Radiol 49(5):580-588. 
12.   Schmitz SA, Coupland SE, Gust R, et al. (2000) Superparamagnetic iron 
oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable 
hyperlipidemic rabbits. Investigative radiology 35(8):460-471. 
13.   Klug K, Gert G, Thomas K, et al. (2009) Murine atherosclerotic plaque 
imaging with the USPIO Ferumoxtran-10. Frontiers in bioscience : a journal and 
virtual library 14:2546-2552. 
14.   Bendszus M & Stoll G (2003) Caught in the act: in vivo mapping of 
macrophage infiltration in nerve injury by magnetic resonance imaging. The 
Journal of neuroscience : the official journal of the Society for Neuroscience 
23(34):10892-10896. 
15.   Stoll G, Wessig C, Gold R, & Bendszus M (2006) Assessment of lesion 
evolution in experimental autoimmune neuritis by gadofluorine M-enhanced MR 
neurography. Experimental neurology 197(1):150-156. 
16.   Beckmann N, Falk R, Zurbrugg S, Dawson J, & Engelhardt P (2003) 
Macrophage infiltration into the rat knee detected by MRI in a model of antigen-
induced arthritis. Magnetic resonance in medicine : official journal of the Society 
of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 
49(6):1047-1055. 
119 
 
17.   Dunn EA, Weaver LC, Dekaban GA, & Foster PJ (2005) Cellular imaging of 
inflammation after experimental spinal cord injury. Mol Imaging 4(1):53-62. 
18.   Beckmann N, Cannet C, Zurbruegg S, et al. (2006) Macrophage infiltration 
detected at MR imaging in rat kidney allografts: early marker of chronic rejection? 
Radiology 240(3):717-724. 
19.   Ye Q, Wu YL, Foley LM, et al. (2008) Longitudinal tracking of recipient 
macrophages in a rat chronic cardiac allograft rejection model with noninvasive 
magnetic resonance imaging using micrometer-sized paramagnetic iron oxide 
particles. Circulation 118(2):149-156. 
20.   Matsushita T, Kusakabe Y, Fujii H, Murase K, & Yamazaki Y (2011) 
Inflammatory imaging with ultrasmall superparamagnetic iron oxide. Magnetic 
resonance imaging 29(2):173-178. 
21.   Ho C & Hitchens TK (2004) A non-invasive approach to detecting organ 
rejection by MRI: monitoring the accumulation of immune cells at the transplanted 
organ. Curr Pharm Biotechnol 5(6):551-566. 
22.   Zhang Y, Dodd SJ, Hendrich KS, Williams M, & Ho C (2000) Magnetic 
resonance imaging detection of rat renal transplant rejection by monitoring 
macrophage infiltration. Kidney Int 58(3):1300-1310. 
23.   Stoll G & Bendszus M (2009) Imaging of inflammation in the peripheral and 
central nervous system by magnetic resonance imaging. Neuroscience 158(3):1151-
1160. 
24.   Vellinga MM, Vrenken H, Hulst HE, et al. (2009) Use of ultrasmall 
superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate 
diffuse inflammation in the normal-appearing white matter (NAWM) of multiple 
sclerosis (MS) patients: an exploratory study. Journal of magnetic resonance 
imaging : JMRI 29(4):774-779. 
25.   Metz S, Beer AJ, Settles M, et al. (2010) Characterization of carotid artery 
plaques with USPIO-enhanced MRI: assessment of inflammation and vascularity as 
in vivo imaging biomarkers for plaque vulnerability. Int J Cardiovasc Imaging. 
26.   Kawahara I, Nakamoto M, Kitagawa N, et al. (2008) Potential of magnetic 
resonance plaque imaging using superparamagnetic particles of iron oxide for the 
detection of carotid plaque. Neurol Med Chir (Tokyo) 48(4):157-161; discussion 
161-152. 
27.   Deserno WM, Harisinghani MG, Taupitz M, et al. (2004) Urinary bladder 
cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. 
Radiology 233(2):449-456. 
28.   Savranoglu P, Obuz F, Karasu S, et al. (2006) The role of SPIO-enhanced 
MRI in the detection of malignant liver lesions. Clin Imaging 30(6):377-381. 
29.   Kim MJ, Kim JH, Choi JY, et al. (2006) Optimal TE for SPIO-enhanced 
gradient-recalled echo MRI for the detection of focal hepatic lesions. AJR Am J 
Roentgenol 187(3):W255-266. 
120 
 
30.   Dousset V, Gomez C, Petry KG, Delalande C, & Caille JM (1999) Dose and 
scanning delay using USPIO for central nervous system macrophage imaging. 
Magma 8(3):185-189. 
31.   Hauger O, Grenier N, Deminere C, et al. (2007) USPIO-enhanced MR 
imaging of macrophage infiltration in native and transplanted kidneys: initial 
results in humans. European radiology 17(11):2898-2907. 
32.   Williams JB, Ye Q, Hitchens TK, Kaufman CL, & Ho C (2007) MRI 
detection of macrophages labeled using micrometer-sized iron oxide particles. J 
Magn Reson Imaging 25(6):1210-1218. 
33.   Wu YL, Ye Q, Foley LM, et al. (2006) In situ labeling of immune cells with 
iron oxide particles: an approach to detect organ rejection by cellular MRI. 
Proceedings of the National Academy of Sciences of the United States of America 
103(6):1852-1857. 
34.   Weaver LC, Verghese P, Bruce JC, et al. (2001) Autonomic dysreflexia and 
primary afferent sprouting after clip-compression injury of the rat spinal cord. J 
Neurotrauma 18(10):1107-1119. 
35.   Rosset A, Spadola L, & Ratib O (2004) OsiriX: an open-source software for 
navigating in multidimensional DICOM images. J Digit Imaging 17(3):205-216. 
36.   Popovich PG, Wei P, & Stokes BT (1997) Cellular inflammatory response 
after spinal cord injury in Sprague-Dawley and Lewis rats. The Journal of 
comparative neurology 377(3):443-464. 
37.   Popovich PG & Hickey WF (2001) Bone marrow chimeric rats reveal the 
unique distribution of resident and recruited macrophages in the contused rat spinal 
cord. Journal of neuropathology and experimental neurology 60(7):676-685. 
38.   Longbrake EE, Lai W, Ankeny DP, & Popovich PG (2007) Characterization 
and modeling of monocyte-derived macrophages after spinal cord injury. Journal of 
neurochemistry 102(4):1083-1094. 
39.   Stirling DP & Yong VW (2008) Dynamics of the inflammatory response after 
murine spinal cord injury revealed by flow cytometry. Journal of neuroscience 
research 86(9):1944-1958. 
40.   Heyn C, Bowen CV, Rutt BK, & Foster PJ (2005) Detection threshold of 
single SPIO-labeled cells with FIESTA. Magnetic resonance in medicine : official 
journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic 
Resonance in Medicine 53(2):312-320. 
41.   Long CM, van Laarhoven HW, Bulte JW, & Levitsky HI (2009) 
Magnetovaccination as a novel method to assess and quantify dendritic cell tumor 
antigen capture and delivery to lymph nodes. Cancer research 69(7):3180-3187. 
42.   Ye Q, Yang D, Williams M, et al. (2002) In vivo detection of acute rat renal 
allograft rejection by MRI with USPIO particles. Kidney Int 61(3):1124-1135. 
43.   Denes A, Vidyasagar R, Feng J, et al. (2007) Proliferating resident microglia 
after focal cerebral ischaemia in mice. Journal of cerebral blood flow and 
121 
 
metabolism : official journal of the International Society of Cerebral Blood Flow 
and Metabolism 27(12):1941-1953. 
44.   Dousset V, Brochet B, Deloire MS, et al. (2006) MR imaging of relapsing 
multiple sclerosis patients using ultra-small-particle iron oxide and compared with 
gadolinium. AJNR. American journal of neuroradiology 27(5):1000-1005. 
45.   Vellinga MM, Oude Engberink RD, Seewann A, et al. (2008) Pluriformity of 
inflammation in multiple sclerosis shown by ultra-small iron oxide particle 
enhancement. Brain : a journal of neurology 131(Pt 3):800-807. 
46.   Oweida AJ, Dunn EA, Karlik SJ, Dekaban GA, & Foster PJ (2007) Iron-oxide 
labeling of hematogenous macrophages in a model of experimental autoimmune 
encephalomyelitis and the contribution to signal loss in fast imaging employing 
steady state acquisition (FIESTA) images. Journal of magnetic resonance imaging : 
JMRI 26(1):144-151. 
47.   Shen J, Zhong XM, Duan XH, et al. (2009) Magnetic resonance imaging of 
mesenchymal stem cells labeled with dual (MR and fluorescence) agents in rat 
spinal cord injury. Academic Radiology 16(9):1142-1154. 
48.   Gilad AA, Walczak P, McMahon MT, et al. (2008) MR tracking of 
transplanted cells with "positive contrast" using manganese oxide nanoparticles. 
Magnetic resonance in medicine : official journal of the Society of Magnetic 
Resonance in Medicine / Society of Magnetic Resonance in Medicine 60(1):1-7. 
49.   Giesel FL, Stroick M, Griebe M, et al. (2006) Gadofluorine m uptake in stem 
cells as a new magnetic resonance imaging tracking method: an in vitro and in vivo 
study. Invest Radiol 41(12):868-873. 
50.   Mani V, Adler E, Briley-Saebo KC, et al. (2008) Serial in vivo positive 
contrast MRI of iron oxide-labeled embryonic stem cell-derived cardiac precursor 
cells in a mouse model of myocardial infarction. Magn Reson Med 60(1):73-81. 
51.   Korosoglou G, Tang L, Kedziorek D, et al. (2008) Positive contrast MR-
lymphography using inversion recovery with ON-resonant water suppression 
(IRON). J Magn Reson Imaging 27(5):1175-1180. 
 
 
122 
 
Chapter 5  
5 Conclusion And Future Directions  
5.1 Clinical Problem 
Spinal cord injury (SCI) remains one of the most devastating conditions in medicine; not 
only are lives lost but also there is a loss of productive life years and a high economic 
burden placed on our society. It is estimated that there are 4,259 (42% traumatic and 58% 
from non-traumatic causes) new SCI cases in Canada each year.1 There are many aspects 
to managing SCI, including specialized medical care, comprehensive rehabilitation and 
specialized equipment to increase independence and support for community reintegration. 
Within the medical care aspect, there are limited therapeutic options following SCI 
though recent work targeting inflammation modulation and stem cell therapy has 
renewed hope that repair and recovery from central nervous system (CNS) trauma is 
possible, albeit there is still a lot of work to do.2 In regards to stem cell therapy, 
important, unresolved questions persist relating to the timing of the treatment, where 
donor cells go after transplantation and how their contribution to the repair of neural 
tissue over time can be monitored.  
5.2 Significance 
Magnetic resonance imaging (MRI) can be used to address these questions by producing 
high-resolution images with exquisite soft tissue contrast in a non-invasive, non-
destructive and three-dimensional (3D) manner, allowing a dynamic view of changing 
pathology and cellular events in vivo. Furthermore, cellular MRI should allow for 
optimizing of transplantation paradigms, starting with delivery efficiency and what 
impact that may have for overall distribution and response to different therapies. Being 
able to monitor cells in vivo in an SCI model may provide valuable information regarding 
cell trafficking and changes in pathology in response to cell therapy, anti-inflammatory 
treatment, or a combination of both.  
One of the key aspects of this project is that it focuses on evaluating SCI and 
experimental cell therapy in vivo using a clinical, whole-body MRI system. As MRI 
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clinical systems have become increasingly available at hospitals, and clinical trials for 
cell therapy for SCI treatment and cell tracking increase, it is important to translate the 
cellular MRI technology we develop for clinical use. MRI offers the potential for non-
invasive evaluation of treatment outcome at several time points making it a promising 
tool for planning and optimizing anti-inflammatory treatments and to maximize stem cell 
survival and engraftment during cell therapy. 
  
5.3 Summary Of Work 
This project involved in vivo imaging of SCI in mouse and rat models using a balanced 
steady state free precession (bSSFP) pulse sequence and a 3T clinical scanner equipped 
with a high-performance gradient coil insert. The imaging technology was optimized to 
allow longitudinal studies in SCI models of both mice and rats. This approach was used 
to assess direct multipotent mesenchymal stromal cell (MSC) transplantation in a mouse 
model and acute inflammation in a rat model. The specific aspects of each chapter are 
summarized below.  
5.3.1 In Vivo MRI Of SCI In The Mouse (Chapter 2) 
In Chapter 2 the feasibility of performing high-resolution in vivo MRI to visualize the 
injured mouse spinal cord using a bSSFP pulse sequence, in a clip compression injury 
model, was presented. High-resolution mouse cord images were used to detect and 
monitor the cord lesions for 6 weeks after SCI. The epicenter of the injury appeared as a 
region of mixed signal intensities on day 2 post-SCI. Regions of signal hypo-intensity 
appeared at the lesion site by 2 weeks post-SCI and became more apparent with time. In 
some mice, large cyst-like lesions were detected rostral to the lesion epicenter, as early as 
2 weeks post-SCI, and increased in volume with time. In addition, MRI was used to 
detect and monitor iron-labeled MSC after their transplantation into the injured cord. 
MSC appeared as large, obvious regions of signal loss in the cord, which decreased in 
size over time. This was the first study to use cellular MRI for cell tracking in vivo in a 
mouse SCI model. 
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5.3.2 The Use Of Cellular MRI To Track The Fate Of Iron-Labeled 
MSC After Direct Transplantation In A Mouse Model Of SCI 
(Chapter 3)  
In Chapter 3, the fate of iron-labeled MSC was tracked with MRI after their direct 
transplantation into mice with SCI. SCI mice received a direct transplant of (1) live MSC 
labeled with micron-sized iron oxide particles (MPIO); (2) dead, MPIO-labeled MSC; (3) 
unlabeled MSC; or (4) free MPIO and were imaged at 3T for 6 weeks after 
transplantation. Live, iron-labeled MSC appeared as a well-defined region of signal loss 
in the mouse spinal cord at the site of transplant. However, the MR appearance of dead, 
iron-labeled MSC and free iron particles was similar and persisted for the 6 weeks of the 
study. While iron-labeled stem cells could be detected and monitored in vivo after direct 
transplantation into the injured spinal cord of mice, the fate of the iron label was not 
clear. Our investigation indicated that caution should be taken when interpreting MR 
images after direct transplantation of iron-labeled cells in SCI. Areas of signal loss were 
not detected in other organs outside the CNS but in a few animals that received live 
MPIO-labeled MSC signal loss was observed along the dorsal edge of the cord in the 
cervical spinal cord, possibly within the CSF.  
5.3.3 In Vivo MRI Of Acute Inflammation After SCI In The Rat: A 
Preliminary Study (Chapter 4) 
In Chapter 4 a preliminary investigation was performed to evaluate techniques for 
macrophage imaging using cellular MRI in a traumatic SCI model in the rat. A clip 
compression SCI was induced in 16 female Wistar rats and they were scanned using a 3D 
bSSFP pulse sequence with 200x200x200µm resolution 3 days after SCI. Molday IONTM, 
an ultra-small super superparamagnetic iron oxide (USPIO) blood pool agent, was 
injected at 3 different doses: 5mg/kg (n=3), 15mg/kg (n=7), and 30mg/kg (n=3); 5 control 
rats were not injected. 24 hours later the rats were imaged again. Areas of signal 
heterogeneity at the epicenter were identified in images of all animals on day 3 and at day 
4 in images of controls. In the animals that received USPIO, additional areas appeared 
hypo-intense on day 4 where the signal loss was more pronounced. Fractional signal loss 
(FSL) was a robust measurement to compare differences in signal hypo-intensity before 
and after the USPIO injection. Histology showed intracellular iron in these animals, 
125 
 
which suggested that the increased signal loss observed after the injection was due to 
intracellular iron accumulation at the lesion site, possibly from macrophages that 
phagocytized the iron agent. Being able to follow this cell infiltration over time may 
contribute to understand changes in timing, severity and patterns as a response to 
potential treatments.  
While most studies in rat SCI models are done at higher field scanners,3-6 we showed the 
feasibility of doing this using a clinical scanner at a high resolution. The fact that the 
present study was done in vivo in a reasonable period of time, with multiple scans and 
without animal mortality lays a foundation to explore potential treatments such as cell 
therapy and anti-inflammatory drug intervention. 
 
5.4 Future directions 
The work presented in this thesis opens up different paths for further investigation 
regarding cellular MRI in SCI research.  
One of the questions regarding cell therapy for SCI treatment is optimal delivery method. 
Different routes have been used such as intra-arterial,7 intravenous,8 lumbar puncture,9 
and direct transplantation.10 However, there is no clear picture of which, if any, would 
produce optimal results. We have shown here how cellular MRI can be used to better 
understand the fate of administered stem cells. From the moment of transplantation we 
were able to verify cell delivery to the target, which as de Vries et al. have reported, may 
be of crucial importance for therapy success.11 Thus, the techniques here developed could 
be applied to compare different transplantation sites and techniques. We were also able to 
observe distribution to other tissues, which might help get a better understanding of the 
homing of the cells and whether that is required for the trophic and immunomodulatory 
effects that stem cells can provide. Especially after the report of increased pain and 
spasticity by Kishk et al.,12 upon cell transplantation, being able to monitor cells over 
time at a high resolution could give us a clearer picture of their distribution. Things to 
investigate might include if cells are going to the sensory tracts, for example, and if this is 
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an undesirable target to home to. As one of the differences among the early clinical 
studies has been dose difference that would be certainly another thing to compare in the 
future with longitudinal studies as shown here. 
One of the limitations in this study was establishing the long-term fate of the cells, as we 
could not distinguish viable and non-viable cells or iron transfer several weeks after the 
transplant. Recent studies have investigated the ability to differentiate between live and 
dead cells based on changes in relaxation times, and contrast, when iron goes from being 
compartmentalized to free in solution.13, 14 These techniques may be useful for 
monitoring cell death in transplantation studies, however, they have yet to be validated in 
vivo. An alternative exciting new development that could be incorporated in cell tracking 
in SCI models is the use of MRI reporter genes. A recent study used embryonic stem 
cells transduced with a reporter gene that can be targeted with an iron oxide conjugated 
antibody to provide information on cell viability, by providing differences in contrast 
from viable cells, even as they divided and differentiated, compared to apoptotic cells.15 
Another study used ferritin as a reporter gene by transducing stem cells to overexpress 
ferritin and then transplanted them into a myocardial infarction model where the authors 
reported the possibility of tracking stem cells as they divide and differentiate while being 
able to track morpho-functional changes in the heart.16 Additional information on cell 
viability specific to the transplanted cells while maintaining MRI sensitivity would 
certainly be useful for cell transplantation in SCI models such as the ones here presented. 
This would help track changes in the cord and lesion while simultaneously track cell 
viability. 
Better understanding macrophage response is important for planning anti-inflammatory 
treatments and cell therapy.17 Imaging macrophage infiltration in vivo will contribute to 
better understand their role in SCI and consider it when optimizing treatments. In the case 
of SCI where there can be different sources of hyper- and hypo- intensity due to 
pathological features of the injury, like edema and hemorrhage combined MRI protocols 
may also help distinguish between iron labeled cells and other sources of hypo-intensity. 
Susceptibility weighted imaging,18, 19 for instance, has shown the ability to detect 
hemorrhage in SCI20 and would be worth trying to distinguish between areas of signal 
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loss from different sources. The development of new pulse sequences, which generate 
positive contrast from iron-labeled cells, could also be incorporated to the techniques 
here developed to better define the signal from iron-labeled cells.21, 22 
The FSL measurement provided useful information for monitoring increased iron in the 
SCI lesion; it was significantly greater in the cord images after USPIO administration. 
However, FSL does not provide rigorous quantification of iron present. New algorithms 
are being developed for iron quantification,23 such as phase gradient mapping to estimate 
iron concentration. Implementing algorithms for cord registration and segmentation 
would certainly improve the ability to quantify the changes observed in signal due to 
USPIO. We have previously used lesion volume measurements in a rat model ex vivo to 
assess an anti-inflammatory treatment.24 A significant difference in the lesion volume 
was measured for treated versus untreated SCI rats. We have now shown that it is 
possible to image the rat in vivo and label cells in situ. Combining this technology of in 
vivo imaging with long-term follow-up of SCI pathological features could be used to 
compare treatments; for example, how stem cell therapy might impact cavity formation in 
the chronic phase.   
SCI is certainly a complex condition and in the end, it is most likely that a combination of 
treatments and a comprehensive rehabilitation will maximize the chances of functional 
recovery and thus improve quality of life of individuals who deal daily with the obstacles 
it poses. There are still questions to be addressed in a wide variety of treatments25, 26 and 
in a field where clinical translation and longitudinal monitoring is so important to decide 
which of these treatments to take forward to clinical trials, cellular MRI could certainly 
be an important part of this process. As these tools are refined, they can be used to test 
different treatments (MSC, mobilization agents, anti-inflammatory or combinations) and 
use information obtained from MRI to establish best treatment time-points to optimize 
treatment effects. 
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